10 Center Drive RM 13N240B Bethesda, MD 20892 Abbreviated Title : Enzalutamide in non-met CSPC
CC Protocol #: 13-C-0153
NCT #: [STUDY_ID_REMOVED]
OSP #:IBC #: 1301-1205RD-13-I-12
Amendment: J
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with 
Non-Metastatic Castration Sensitive Prostate Cancer
NCI Principal Investigator:Ravi Madan, M.D.
A, B, C, D, E, F
Genitourinary Malignancies Branch, CCR, NCI
10 Center DriveBuilding 10, Room 13N240Bethesda, MD 20892Phone: (301) 480-7168Email: madanr@mail.nih.gov
Statistician: Seth Steinberg, Ph.D., OCD, CCR, NCIE, F
NIH Associate Investigators: James Gulley, M.D., PhD, GMB, CCR, NCIA, B, C, D, E, F
William Dahut, M.D., GMB, CCR, NCIA, B, C, D, E, F
Marijo Bilusic, M.D., PhD, GMB, CCR, NCIA, B, C, D, E, F
Anna Couvillon, CRNP, GMB, CCR, NCIA, B, C, D, E, F
Amy Hankin, P.A., GMB, CCR, NCI A, B, C, D, E, F
Myrna Rauckhorst, R.N., OCD, CCR, NCIA, B, C, E, F
Sheri McMahon, R.N., OCD, CCR, NCIA, B, C, E, F
Jennifer Marte, M.D., GMB, CCR, NCIE, F
Fatima Karzai, M.D., GMB, CCR, NCIA, B, C, D, E, F
Julius Strauss, M.D., LTIB, CCR, NCIA, B, C, D, E, F
Guinevere Chun, R.N., OCD, CCR, NCIA, B, C, E, F
Helen Owens, R.N., OCD, CCR, NCIA, B, C, E, F
Referral Contact:
Study Coordinator: Anna Couvillon, C.R.N.P.Helen Owens, R.N., OCD, CCR, NCI
10 Center Drive, 13N244Bethesda, MD 20892Phone: 240-760-6068Email: helen.owens@nih.gov
Non-NIH Associate Investigators: Philip M. Arlen, M.D. [V], GMB, CCR, NCIA, B, E, F
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
2Collaborators: Nima Sharifi, M.D.F,G
Cleveland Clinic Foundation
Lerner Research Institute9500 Euclid AvenueCleveland, Ohio 44195sharifn@ccf.org
Roles: A. Obtain information by intervening or interacting 
with living individuals for research purposes
B. Obtaining identifiable private information about 
living individuals
C. Obtaining the voluntary informed consent of 
individuals to be subjects
D. Makes decisions about subject eligibilityE. Studying, interpreting, or analyzing identifiable 
private information or data/specimens for 
research purposes
F. Studying, interpreting, or  analyzing de-identified 
data or specimens for research purposes
G. Some/all research activ ities performed outside 
NIH
Investigational Agents:    
Drug Name: Enzalutamide PROSTVAC-V/F
IND Number: 15455 15455
Sponsor: Center for Cancer Research, NCI Center for Cancer Research, 
NCI
Manufacturer: Medivation and Astella s, Inc. Bavarian Nordic, Inc.
Supplier Medivation and Astellas, Inc. Bavarian Nordic, Inc.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
3PRÉCIS
Background
xAndrogen deprivation therapy (ADT) and surveillance are standard therapy options for 
prostate cancer patients with  biochemical progression afte r localized therapy (or non-
metastatic castration sensitive prostate cancer; nmC SPC also known as D0 Prostate 
Cancer). These patients cannot be cured of pr ostate cancer and the primary therapeutic 
goal is to contain the disease with anti-androgen therapy.
xADT can be administered intermittently consisting of multiple short courses or continuously with similar long-term clinical outcomes.
xPrevious studies with high dose bicalutamide (androgen receptor antagonist, ARA) haveshown significant biochemical control in nmCSPC.
xEnzalutamide is a modern ARA with greater andr ogen receptor affinity than bicalutamide 
and further impairs downstream effects of a ndrogen receptor activation. This agent is 
FDA approved for the treatment of chemot herapy refractory metastatic castration 
resistant prostate cancer.
xGiven its favorable side effect profile, there is strong interest in using enzalutamide to 
treat patients with earlier stages of prostate cancer including nmCSPC.
xPSA-TRICOM (Prostvac™; developed by the National Cancer Institute [NCI] and licensed to Bavarian Nordic, Mountain View , CA) is a novel candidate prostate cancer 
immunotherapy for the treatment of  prostate cancer. It is a vi ral vector based therapeutic 
cancer vaccine that is administered via s ubcutaneous injections. In a randomized 
controlled Phase 2 trial, PSA-TRICOM therapy  was associated with a prolongation of 
survival in men with metastatic castrate-resistant prostate cancer. A phase III trial is 
currently enrolling patients in this same population.
xThere is also rationale to use therapeutic cancer vaccines such as PSA-TRICOM in earlier stage prostate cancer patients to maximize the potential therapeutic effect of immune stimulating therapy.
xAn ongoing NCI clinical trial that combined PSA-TRICOM with flutamide (an older 
FDA approved ARA) in nonmetastatic castrat ion resistant pros tate cancer has 
demonstrated safety and suggested the potential to improve time to progression.
xAnalysis of previous trials using therapeutic cancer vaccines alone and in combination suggests that such therapies may alter tumor growth rate. If this hypothesis is correct, a 
therapeutic cancer vaccine may alter tumor regrowth rate/recovery after a cytoreductive therapy such as enzalutamide is discontinued.
xIf PSA-TRICOM with enzalutamide can result in a reduced tumor regrowth rate as 
measured by PSA after a short course of enzalutamide therapy, it would provide an 
important proof of concept and potentially define it more clear role for therapeutic cancer 
vaccines in prostate cancer and potentially other cancers.
xTo prospectively evaluate this hypothesis, all patients will be treated with enzalutamide in 
a manner similar to how short course ADT is used in common clinical practice. Half the 
patients will also be given PSA-TRICOM and PSA recovery after enzalutamide therapy will be compared between patients who received vaccine and those who did not.
xPreliminary data from the first cohort of ra ndomized patients suggests that enzalutamide 
alone can induce an immunologic response.  A second cohort of 15 patients will explore a 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
4lower dose of enzalutamide at 80 mg to de termine if similar immunologic responses can 
also be seen at a lower dose, where toxicity is less likely.
Objectives
Primary Endpoint:
xDetermine if PSA-TRICOM combined with the novel androgen receptor antagonist 
enzalutamide will result in a decrease in PSA growth kinestics (tumor re-growth rate)after enzalutamide discontinua tion in patients with non-meta static, castration sensitive 
prostate cancer (i.e. patient s with normal testosterone).
Eligibility
xPatients with nonmetastatic cas tration sensitive prostate ca ncer and a PSA over 2.0 ng/ml
xPatients with normal testosterone levels.  
xHistologically confirme d adenocarcinoma.    
xPatients with a PSA doubling time of 12 months or less. 
xECOG 0-1.
Design
xRandomized pilot study
xCohort 1:
Thirty-four patients to be en rolled and randomized 1:1 to 
oArm A: Enzalutamide for 3 months.
oArm B: Enzalutamide 3 months + PSA-TRICOM on weeks 1, 3,5,9,13,17 and 21. 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
5xEnzalutamide will be given at the standard dose of 160 mg daily for 3 months.  PSA-
TRICOM (Prostvac-V/F) will consist of a single subcutaneous (sc) immunization of 
Prostvac-V in Week 1, followed by 6 Prostvac-F immunizations administered in Weeks 3, 5, 9, 13, 17, and 21. Patients will be re treated with a 3-month course  of enzalutamide after PSA 
has returned to baseline values at study entry or higher.  Patients will have had to be on study for at least 7 months or longer in order to  be retreated with an  additional course of 
enzalutamide therapy.  Patients will be followed for PSA recovery after enzalutamide has been discontinued. Patients who do not develop a 25% decline in PSA after 3 months will not be evaluated for tumor re-growth and additional patients will be enrolled to evaluate for that endpoint. Patients will be stratified based on a doubling time of  greater than or less than 6 
months.  
R
A
ND
O
M
I
Z
E
Arm A: Enzalutamide (n=17)
Arm B: Enzalutamide + PSA-TRICOM (n=17)
Cohort 1
Arm A: Enzalutamide (n=17)
Arm B: Enzalutamide + PSA-TRICOM (n=17)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
6TABLE OF CONTENTS
SUMMARY OF CHANGES......................................................... Error! Bookmark not defined.
PRÉCIS......................................................................................................................... ...................3
TABLE OF CONTENTS.................................................................................................................6
1 INTRODUCTION .............................................................................................................11
1.1 Study Objectives ....................................................................................................11
1.1.1 Primary.......................................................................................................11
1.1.2 Secondary...................................................................................................11
1.2 Background and Rationale.....................................................................................11
1.2.1 Enzalutamide..............................................................................................111.2.2 Therapeutic Cancer Vaccin es in Prostate Cancer ......................................13
1.2.3 PSA-TRICOM ...........................................................................................141.2.4 Rationale for Combining En zalutamide with PSA-TRICOM ...................15
1.2.5 Combining Androgen Receptor Antagonists with PSA-TRICOM, 
clinical evidence.........................................................................................16
 ................................................16
1.2.6 Enzalutamide’s Immune Eff ects in Preclinical Models.............................16
1.2.7 Rationale for conducting the study in nmCSPC patients...........................18
1.2.8 The Importance of Evaluating the Immunologic Response.......................181.2.9 Change in regrowth rate as endpoint .........................................................19
1.2.10 Tumor Growth Kinetics .............................................................................21
1.2.11 Rationale for Re-Treatment of Patients with a Se cond Course of 
Enzalutamide..............................................................................................22
1.2.12 Rationale for Evaluating Change s in Testoster one and Related 
Hormone Levels.........................................................................................22
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT....................................................23
2.1 Eligibility Criteria ..................................................................................................23
2.1.1 Inclusion Criteria .......................................................................................232.1.2 Exclusion Criteria ......................................................................................242.1.3 Recruitment Strategies...............................................................................26
2.2 Screening Evaluation .............................................................................................262.3 Registration Procedures .........................................................................................262.4 Treatment Assignment and Randomiz ation/Stratifica tion Procedures..................26
2.5 Baseline Evaluation ...............................................................................................27

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
73 STUDY IMPLEMENTATION .........................................................................................27  
3.1 Study Design..........................................................................................................27  
3.1.1  Protocol Stopping Rules ............................................................................28  
3.2 Drug Administration ..............................................................................................29  
3.3 Treatment Modifications........................................................................................29  
3.3.1  Vaccine ......................................................................................................29  
3.3.2  Enzalutamide..............................................................................................30  
3.4 Protocol Evaluation (see Appendix C ) .................................................................30  
3.4.1  All patients who are deemed elig ible and who sign an informed 
consent will be enrolle d in this trial...........................................................30  
3.4.2  A complete history and physical  examination, including ECOG 
performance status, will be done within 16 days before enrollment. ........30  
3.4.3  Laboratory Studies.....................................................................................30  
3.4.4  Radiographic assessment ...........................................................................31  
3.4.5  Assessment for PSA-TRICOM administration (Arm B)...........................31  
3.5 Concurrent Therapies.............................................................................................31  
3.6 Criteria for Removal from Protocol  Therapy and Off Study Criteria....................31  
3.6.1  Criteria for removal from protocol therapy ...............................................31  
3.6.2  Off-Study Criteria ......................................................................................32  
3.6.3  Off Protocol Therapy an d Off-Study Procedure........................................32  
3.7 Post-Study Evaluation (Follow-Up) ......................................................................32  
4 BIOSPECIMEN COLLECTION.......................................................................................32  
4.1 Correlative Studies  for Re search ...........................................................................32  
4.1.1  Immunologic Parameters ...........................................................................32  
4.1.2  Collection of Research (I mmunologic) Blood Samples ............................33  
4.1.3  Immunologic Assays..................................................................................34  
4.1.4  Additional Assays ......................................................................................35  
4.1.5  Plasma VEGF levels ..................................................................................36  
4.1.6  Serum Analysis ..........................................................................................36  
4.2 Storage and Tracking of Collected Blood Samples ...............................................37  
4.2.1  Protocol Completion/Sa mple Destruction .................................................38  
5 SUPPORTIVE CARE........................................................................................................38  
5.1 Excluded medications ............................................................................................39  
5.2 Treatment of vaccinia vaccination complication ...................................................39  
5.2.1  Vaccinia Immune Globulin:.......................................................................39  
5.2.2  Cidofovir (Vistide®, Gilead Sciences):.....................................................40  
6 DATA COLLECTION AND EVALUATION..................................................................40  
6.1 Data Collection ......................................................................................................40  
6.1.1  Eligible patients must be confirmed and checklist completed. 
Consent form must be signed prior to registration with Central Registration Information Services. ............................................................40
 
6.1.2  Data will be secured in NCI C3D database.  Data will be collected using protocol-specific case report forms, and verified for accuracy 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
8and completeness.  Hard copies of data will be stored in locked 
secured areas and data will be entered onto a secured electronic data base. The following protocol-specific study forms will be complete and stored: eligibility checklist (developed by Central Registration Office, CRO). A copy of all serious AE forms will be kept in the rese arch re cord. ........................................................................40
 
6.1.3  Treatment is given according to protocol (dated notes about doses given, complications, and clinical outcomes)............................................40
 
6.1.4  Toxicity is assessed according to pr otocol (laboratory report slips, 
etc.).............................................................................................................40  
6.1.5  Response is assessed according to protocol (X-ray, scan, lab reports, and date noted on clini cal assessment, as appropriate).................40
 
6.1.6  Drug Accountability Records are kept for each patient.............................40  
6.1.7  We will not report Grade 1 adverse events................................................40  
6.2 Response Criteria...................................................................................................41  
6.2.1  Disease Progression ...................................................................................41  
6.3 Toxicity Criteria.....................................................................................................42  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN ......................................................................................................42
 
7.1 Definitions..............................................................................................................42  
7.1.1  Adverse Event............................................................................................42  
7.1.2  Suspected adve rse reaction ........................................................................42  
7.1.3  Unexpected adve rse reaction .....................................................................42  
7.1.4  Serious........................................................................................................43  
7.1.5  Serious Adverse Event...............................................................................43  
7.1.6  Disability....................................................................................................43  
7.1.7  Life-threatening adve rse drug ex perience..................................................43  
7.1.8  Protocol Deviation (NIH Definition).........................................................43  
7.1.9  Non-compliance (NIH Definition).............................................................43  
7.1.10  Unanticipated Problem...............................................................................43  
7.2 NCI-IRB and Clinical Director Reporting.............................................................44  
7.2.1  NCI-IRB and NCI CD Expedite d Reporting of Unanticipated 
Problems and Deaths..................................................................................44  
7.2.2  NCI-IRB Requirements for PI Reporting at Continuing Review ..............44  
7.2.3  NCI-IRB Reporting of IND Safety Reports...............................................44  
7.3 IND Sponsor Reporting Criteria ............................................................................45  
7.3.1  Reporting Pregnancy..................................................................................45  
7.4 Safety Reporting Criteria to th e Pharmaceutical Collaborators.............................45  
7.4.1  Reporting to Astellas..................................................................................45  
7.4.2  Reporting to Bavarian Nordic, Inc.............................................................46  
7.5 Institutional Biosafety Committee (IBC) Reporting Criteria.................................46  
7.5.1  Serious Adverse Event Reports to OSP/IBC .............................................46  
7.5.2  Annual Reports to IBC...............................................................................46  
7.6 Data and Safety Monitoring Plan...........................................................................47  
7.6.1  Principal Investigator/Research Team .......................................................47  
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
97.6.2  Sponsor Monitoring Plan ...........................................................................48  
8 STATISTICAL CONSIDERATIONS...............................................................................48  
8.1.1  Cohort 1 .....................................................................................................48  
8.1.2  Halting Rules .............................................................................................49  
8.1.3  The regression-growth equation ................................................................49  
8.1.4  Data Analysis.............................................................................................49  
9 COLLABORATIVE AGREEMENTS ..............................................................................50  
9.1 Agreement Type.....................................................................................................50  
9.1.1  Cooperative Research and Deve lopment Agreement (CRADA)...............50  
9.1.2  Material Transfer Agreement (MTA) ........................................................50  
10 HUMAN SUBJECT PROTECTIONS ..............................................................................51  
10.1  Rationale for Subject Selection..............................................................................51  
10.1.1  Selection Based on Gender , Ethnicity, and Race.......................................51  
10.1.2  Strategies/Procedures for Recruitment ......................................................51  
10.1.3  Justification for Exclusions........................................................................51  
10.2  Participation of Children........................................................................................51  
10.3  Participation of NIH Subjects Unable to Give Consent.........................................51  
10.4  Evaluation of Benefits /Risks/Discomforts.............................................................52  
10.4.1  Alternative Approach es or Treatments ......................................................52  
10.4.2  Procedures to Eliminate or Minimize Potential Risks ...............................52  
10.4.3  Provisions for Monitoring Data Collection to Ensure Subject 
Safety 52  
10.5  Risks/Benefits Analysis .........................................................................................52  
10.6  Consent and Assent Proc ess and Documentation ..................................................53  
10.6.1  Telephone Re-Consen t Procedure..............................................................53  
10.6.2  Informed Consent of Non-English Speaking Subjects ..............................53  
11 PHARMACEUTICAL AND INVESTIGATIONAL DEVICE INFORMATION ...........54  
11.1  Recombinant Fowlpox-PSA(L155)/TRICOM ...................................................54  
11.1.1  How Supplied.............................................................................................54  
11.1.2  Preparation .................................................................................................55  
11.1.3  Storage .......................................................................................................55  
11.1.4  Stability......................................................................................................55  
11.1.5  Route of Administration ............................................................................55  
11.1.6  Special Handling........................................................................................55  
11.2  Recombinant Vaccinia-PSA(L155)/TRICOM ...................................................57  
11.2.1  How Supplied.............................................................................................58  
11.2.2  Preparation .................................................................................................58  
11.2.3  Storage .......................................................................................................58  
11.2.4  Stability......................................................................................................58  
11.2.5  Route of Administration ............................................................................58  
11.2.6  Special Handling and Precautions .............................................................58  
11.3  Cidofovir (Vistide®, Gilead Sciences) ..................................................................68  
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
1011.4  Enzalutamide..........................................................................................................68  
11.4.1  Description and formulation ......................................................................68  
11.4.2  Source 68  
11.4.3  Storage .......................................................................................................68  
11.4.4  Stability......................................................................................................68  
11.4.5  Dosage and Administration........................................................................69  
11.4.6  Adverse E ffects..........................................................................................69  
11.4.7  Drug Interactions .......................................................................................70  
12 REFERENCES ..................................................................................................................71  
13 Appendix A: Performance Status Criteria .........................................................................76  
14 Appendix B: Vaccinia-PSA(L155)/TRICOM Patient Instruction Sheet...........................77  
15 Appendix C : On Study and Follow-Up Evaluations.........................................................80  
16 Appendix D: Instructions for Pre- Study and Follow-Up Blood Tests...............................88  
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
111 INTRODUCTION
1.1 S TUDY OBJECTIVES
1.1.1 Primary1.1.1.1 Determine if PROSTVAC-V/F combined with the novel ARA enzalutamide will result
in a decrease in PSA growth kinetics after enzalutamide discontinuation in patients with 
non-metastatic, castration se nsitive prostate cancer (i .e. patients with normal 
testosterone).
1.1.2 Secondary 
1.1.2.1 Determine the impact of enzalutamide on PSA as a single agent in patients with normal 
testosterone and non-meta static, castration sens itive prostate cancer
1.1.2.2 Evaluate the immune response in patients treated with both the combination of PSA-
TRICOM and enzalutamide compared to enzalutamide alone. Immune response 
evaluation will include CD4 cells, CD 8 cells, PSA-specific T-cells, natural killer cells, Regulatory T-cells, cytokines, anti-glycan  antibodies and naïve thymic emigrants.
1.1.2.3 Associate immunologic outcomes with PSA responses. 
1.1.2.4 Evaluate the toxicity of enzalutamid e and PSA-TRICOM combination in Arm B and 
compare to enzalutamide alone in Arm A.
1.1.2.5 Evaluate PSA responses to a second 3-month c ourse of enzalutamide in  patients eligible 
for re-treatment based on the protocol.
1.1.2.6 Evaluate changes in testosterone and relat ed hormone levels and each follow up visit, 
and pre-Enzalutamide adminis tration, and 1 hour post, 24 hours post, 48 hours post, and 
72 hours post administration, when logistically feasible. 
1.1.2.7 Evaluate plasma VEGF levels at the st art and end of each patient’s second 12-week 
course of Enzalutamide.
1.1.2.8 Evaluate the immune response in patients treated with enzalutamide at 80 mg/day.
Immune response evaluation will include CD 4 cells, CD 8 cells, PSA-specific T-cells, 
natural killer cells, Regulatory T-cells, cy tokines, anti-glycan antibodies and naïve 
thymic emigrants.
1.2 B
ACKGROUND AND RATIONALE
1.2.1 Enzalutamide
Enzalutamide is a modern update of the orig inal androgen receptor antagonists (ARAs),
the last of which was developed over 2 decades ago. Since then, the prevailing focus shifted to 
chemotherapy and chemotherapy combinations ( 1). In addition to binding to the androgen 
receptor with greater affinity than standard ARAs, enzalutamide prevents downstream effects including nuclear translocation, DNA bindi ng, and signaling to co-activators ( 2). Furthermore, 
enzalutamide has not demonstrated any agonist properties unlike previous ARAs which showed 
agonist properties in approximately 15%-20% of patients ( 3,4). (Figure 1) . Another important 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
12characteristic is that unlike the modern androgen-biosynthesis inhibitor abiraterone, 
enzalutamide does not require daily prednisone.  (Long-term prednisone could have additional 
side effects and could impact the immune re sponse.) The U.S. Food and Drug Administration 
(FDA) approved enzalutamide for metastatic prostate cancer in docetaxel-refractory patients in 
August, 2012 ( 5).
Figure 1
A Phase I/II study of enzalutamide demonstrat ed safety and suggested efficacy in both 
chemotherapy-naïve and chemotherapy-treated castration-resistant prostate cancer (CRPC) 
patients, the vast majority of whom had metastatic disease ( 6).  Two phase III studies were then 
launched in metastatic CRPC (mCRPC). One st udy enrolled chemotherapy-naïve patients; the 
other (AFFIRM) evaluated patients who had progressive disease on docetaxel.  AFFIRM 
enrolled 1199 patients with progressive mCRPC on docetaxel and randomized them 2:1 to 
enzalutamide 160 mg/day (n=800) or placebo (n= 399).  The overall survival favored patients 
randomized to the enzalutamide arm 18.4 to 13.6 months.  This 4.8 months improvement in 
survival represented a 37% risk reduction in  death (hazard ratio 0.63; 95% CI: 0.53 to 0.75; 
P<0.001) the largest relative and absolute improvement in overall survival in an appropriately 
powered phase III study in prostate cancer.  Me dian TTP based on radiographic findings was 8.3 
vs. 2.9 months; HR: 0.40; P<0.001). ( Figure 2 )   Modest increases in fatigue, hot flashes, 
diarrhea, musculoskeletal pain, and headaches re ported in the enzalutamide group, but this was 
possibly related to the substa ntially longer monitoring time for patients on this treatment 
compared to the placebo group.  Therefore, ther e were no significant c oncerns about the side 
effect profile of enzalutamide compared to placebo ( 7). The U.S. FDA approved enzalutamide 
for chemotherapy-refractory mCRPC patients in August of 2012 ( 5). The second phase III trial in 
chemotherapy naïve patients is ongoing.

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
13Figure 2 .  Enzalutamide demonstrates improved overall survival in
mCRPC patients previously treated with docetaxel ( 7).
The ultimate role of enzalutamide in the treatment of prostate cancer will likely be in 
earlier-stage disease. The minimal side effects of enzalutamide in patients with advanced disease 
will create strong interest in providing this therapy for chemotherapy- naïve mCRPC and even 
patients with non-metastatic disease, thus supplanting th e use of older ARAs such as 
bicalutamide which are commonly us ed in non-metastatic patients ( 8).  Also, unlike the modern 
androgen-biosynthesis inhibitor abiraterone, en zalutamide does not requi re daily prednisone. 
Enzalutamide therapy will thus avoid prednisone ’s potential long-term side effects in earlier 
stage disease, an important cons ideration for future treatment st rategies in this population.   
Combination with immune based therapies is attractive because unlike abiraterone, this treatment does not require prednisone which can be immunosuppressive.  In addition, given the data which suggest that hormonal therapies can enhance immune response, it would be valuable to gain a better understanding of the immune impact of enzalutamide given the emerging role of immunotherapy in prostate cancer ( 9). 
At this time, there is no data for the role of enzalutamide in non- metastatic, castration-
sensitive prostate cancer (nmCSPC) patients with normal testosterone.  (Hereafter in this document, nmCSPC will also refer to patients with a normal testoster one and thus presumed 
sensitivity to castration.)  Previously, the first- generation ARA, bicalutamid e, has been evaluated 
in the nmCSPC setting as patients and clinicians seek ways to avoid/delay the symptoms associated with ADT.  Forty-one patients with nmCSPC were treated with high-dose (150 mg) 
bicalutamide, with a secondary addition of finasteride but no androgen suppression therapy. Thirty-four of 36 evaluable patie nts reached a PSA nadir that re presented a decline of PSA by 
95.5%.  The median time to trea tment failure was 21.3 months ( 10).  This time frame was 
consistent with other trials that evaluated high dose bicalutamide in castration-sensitive metastatic disease ( 11).  Based on these findings, the use of single agent enzalutamide in this 
population would be interesting to evaluate given the limited favorable  side effect profile and the 
possibility that enzalutamide is more efficacious than bicalutamide.
1.2.2 Therapeutic Cancer Vacc ines in Prostate Cancer
The goal of therapeutic cancer vaccines is to generate a targeted immune response leading to 
immune-mediated anti-tumor activity.  Sipuleucel-T is a therapeutic cancer vaccine generated from peripheral blood mononuclear cells obtained from individual patient s via leukapheresis. 
This vaccine is generated after a patient’s  peripheral immune cells are collected via 

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
14leukapheresis, transported to a regional processing  center where they are exposed in vitro to a 
PAP/GM-CSF fusion protein. At the end of this process, the activated cellular product is re-
infused into the patient. A full course of therapy repeats this process 3 times every 2 weeks for 1 month ( 12,13).  A phase III trial (n = 512) demonstr ated an overall survival benefit for the 
vaccine (25.8 months vs. 21.7 months; P = 0.032) ( 14). Based on these overall survival findings, 
the FDA approved sipuleucel-T for the treatment of asymptomatic or minimally symptomatic mCRPC, making it the first FDA-approved therapeutic cancer vaccine for the treatment of any malignancy. 
1.2.3 PSA-TRICOM
PSA-TRICOM (Prostvac™; developed by the National Cancer Institute [NCI] and licensed to 
Bavarian Nordic, Mountain View, CA), an off-the-s helf therapeutic cancer vaccine, offers an 
alternative strategy ( 15,16).  (The LTIB and Bavarian Nordichave an ongoing CRADA for the 
preclinical and clinical developm ent of PSA-TRICOM.)  To target prostate-specific antigen (PSA), 
PSA-TRICOM vaccine employs genetically altered poxviruses to deliver targeting information to 
immune cells and generate an imm une response. Administered subcutaneously, the poxviruses deliver 
the transgenes for the tumor associated antigens (PSA) to antigen presenting cells through cellular infection. Once these pox viruses are within the cellu lar cytoplasm, the transgenes are processed. The 
end result is an antigen presenting cell expressing a PSA peptide within the major histocompatibilitycomplex, resulting in PSA-specific cy tolytic T lymphocytes activation ( 17,18). (Figure 4 ) This 
approach does not require expensive, labor-intensive ex vivo preparation of patients’ peripheral blood.
PSA-TRICOM is thus potentially more logistically and financially feasible over the long-term than sipuleucel-T ( 19).
PSA-TRICOM has been investigated in 2 pha se II trials in mCRPC, both of which 
administered the vaccine at monthly intervals until disease progression. An industry-sponsored, 
placebo-controlled, multicenter trial in 125 mCRPC patients randomized them 2:1 in favor of 
PSA-TRICOM; the placebo was an empty poxviral v ector containing no transgenes. As was seen 
in the sipuleucel-T studies, patients receiving vaccine showed no change in TTP, yet had an overall survival benefit (25.1 months with PSA-TRICOM vs. 16.6 months with placebo; P =
0.0061) ( 20).  ( Figure 3 ) A second phase II study of PSA-TRI COM of 32 mCRPC patients at the 
NCI demonstrated that the vaccine was able to  generate a T-cell specific immune response and 
patients with the greatest magnitude of this response had superior outcomes ( 21). Based on the 
findings in these trials, a phase III trial of  PSA-TRICOM in mCRPC is currently underway ( 22).
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
15Figure 3. Poxviral vaccine strategy: Modified poxvirus 
contains transgenes for the tumor-associated antigen PSA 
and 3 T-cell costimulatory molecules ( 16)
Figure 4. PSA-TRICOM improved survival in mCRPC patients in 
a randomized multi center phase II. ( 20)
Like enzalutamide, PSA-TRICOM is very well-tolerated, with common side effects of grade 1 
injection-site reactions or flu-like symptoms ( 20,21). Also like enzalutamide, favorable side 
effect profile and the potential ability to induce a sustained antitumor immune response, clinical 
trials are ongoing evaluating strategies to use PSA-TRICOM in earlier disease patients.
A phase III trial ([STUDY_ID_REMOVED]) of  Prostvac monotherapy, however, was reported to have not 
met its primary endpoint of overa ll survival in September, 2017. Nonetheless, the combination 
of Prostvac and enzalutamide remains scientifically rational and this trial will continue.  
Furthermore, at this point neither this trial nor the phase III trial have su ggested a safety concern 
for Prostvac.
1.2.4 Rationale for Combining En zalutamide with PSA-TRICOM
Accumulating data demonstrate that androgen-deprivation therapy (ADT) affects not 
only prostate cancer growth, but also the immune  system and suggest that ADT in prostate 
cancer can augment the immune response by incr easing T-cell infiltrati on into the prostate (9).
The impact of this T-cell trafficking would be even greater if T cells were primed by a vaccine 
prior to ADT ( 23).  Furthermore, ADT has been shown to decrease immune tolerance of self 
antigens that are over-expressed in many canc ers, increase the production of new T-cells from 

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
16the thymus ( Table 1 ), and enhance the Cytotoxic T-cell repertoire ( 9,24-26 ).   Of the two 
modern anti-androgen therapies for prostate canc er that have emerged in the last few years, 
enzalutamide is preferred over abiraterone, beca use abiraterone requires prednisone which may 
influence the immune response in a vaccine-based combination regimen.
Baseline After ADT
Naïve CD4 cells 3.25%            
of CD3+ cells3.95%            
of CD3+ cellsp = 0.0060
T-Cell Receptor 
Excision Circles93               
per 100,000 cells147              
per 100,000 cellsp = 0.0025
Table 1. ADT Increases Naïve T-cell Emigrants from the Thymus. A previous NCI trial 
([STUDY_ID_REMOVED]) evaluated naïve T-cell emigrants from the thymus after 3 months of ADT.
T-cell receptor excision circles are detectable by products of thymic generation of new T-cells and 
provide a way to quantify such cells.  Naïve CD4 cells are defined by flow cytometry as 
described in the correlative studies section below.  By both measures there was a significant 
increase in the number of naïve T-cells which potentially can be activated by vaccine. 
(unpublished)
1.2.5 Combining Androgen Receptor Antagonists with PSA-TRICOM, clinical evidence
An ongoing clinical trial at the NCI is combining PSA-TRICOM with flutamide, an FDA 
approved ARA, in men with non-metastatic CRPC (N CT00450463) .  Patients are randomized to 
either PSA-TRICOM with flutamide or flutam ide alone.  The primary endpoint is TTP as 
determined by PSA (Bubley criteria) or development of metastatic disease ( 28). An interim
analysis with about half the patients accrued de monstrated that these 2 agents can be safely 
combined with minimal toxicity. The interim TTP analysis favored the combination of PSA-
TRICOM and flutamide compared to fl utamide alone (192 days vs. 108 days) ( 29).(Figure 5 ) The 
study is completing accrual at the NCI and the Cancer Institute of New Jersey, but the interim analysis provides a preliminary clinical rationale for the combination of PSA-TRICOM with a modern ARA in chemotherapy-naï ve patients with mCRPC. The proposed trial in mCRPC will 
use metastatic progression as an  endpoint, which is a more establ ished therapeutic measure than 
criteria currently establishe d for nonmetastatic disease ( 30).
1.2.6 Enzalutamide’s Immune Effects in Preclinical 
Figure 5 . Patient Population: “Biochemical 
Recurrence” or Rising PSA after surgery or RT 
with normal testosterone (nmCSPC)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
17Models
Enzalutamide has been evaluated preclinically by Dr. James Hodge of the Laboratory of 
Tumor Immunology and Biology (LTIB) at the NC I.  The first objective was to determine the 
appropriate dose to use in evaluation of the male C57BL/6 mice.  Doses at 1, 10, 50 and 100 
mg/day were evaluated and the 10 mg/day dose wa s found to be most appr opriate given that it 
achieved a serum concentration of 20 ug/ml, consistent with serum levels in humans. Therefore,
that was the dose evaluated in male C57BL/6 mice. ( Figure 6A ) It was confirmed that 
enzalutamide at 10 mg/day had a significant decrease in the weight of the genitourinary organs after 14 days of dosing, demonstrating the physio logic effects of enzalutamide at 10 mg/day dose 
level. Figure 6B )
Figure 6. Enzalutamide mediates a reduction in 
genitourinary (GU) weight. (A) Concentration of 
Enzalutamide in plasma of mice on Enzalutamide daily diet.  
Male C57BL/6 mice (n=3) were treated with Enzalutamide at different calculated target daily doses (0, 1, 10, 50, and 100mg) 
for 14 days.  On day 15, blood was collected and Enzalutamide
concentration in the plasma was determined. (B) Exposure to 
Enzalutamide causes reduction of GU weight.  Male C57BL/6 
mice (n=7) were not treated (open circles) or treated with 
Enzalutamide (closed circles) for 14 days.  On day 15, mice were sacrificed and their GU and were harvested and weighed. 
All experiments were done three times with similar results.  Statistical analyses were done by Student’s t-test
From an immunologic standpoint, complete blood counts and Fluorescence-activated cell sorting 
analysis of immune cell subpopulations were foun d to be unchanged.  Furthermore, functional 
analysis based on mixed lymphocyte response and CD3-induced proliferation assays of CD4 
cells demonstrated no significant differences.  In  addition, similar to previous studies with 
hormonal therapies, enzalutamide treatment was associated with increased thymic weights and increased T-cell excision circles, consistent w ith the production of new T-cells from the thymus. 
(Figure 7 ) This series of experiment s (publication pending) provide s evidence that enzalutamide
likely will not diminish the quantity or functionality of immune cells and may even enhance thymic production of naïve T-cells, allowing fo r potential immune stimulation by a therapeutic 
cancer vaccine such as PSA-TRICOM. 
Figure 7 .A. Enzalutamide mediates an enlargement of 
thymus and an increase in T-cell Receptor Excision Circles 
(TREC) levels.  (A) . Male C57BL/6 mice (n=7) were not 
treated (open circles) or treated with Enzalutamide (closed 
circles) for 14 days.  On day 15, mice were sacrificed, and 
their thymi harvested and weighed.  (B). Enzalutamide
significantly increases T-cell Excision Circle (TREC) 
levels in male mice.  Male C57BL/6 mice (n=7) were not 
treated (open circles) or treated with Enzalutamide (closed circles) for 14 days.  On day 15, 100ng of DNA from blood 
was collected and TREC levels were quantified by RT-PCR 
in triplicate.  Results were normalized against the cons tant gene segment of TCRA, which serves as endogenous 
reference gene.  All experiments were done three times with similar results.  Statistical analyses were done by 
Student’s t-test

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
181.2.7 Rationale for conducting th e study in nmCSPC patients
The standard of care for patients with nm CSPC includes ADT and active surveillance.  
Generally, these patients can be followed without  therapy until their PSA doubling time escalates 
at which time ADT is often starte d.  All patients in the proposed tr ial will receive enzalutamide.  
Based on previous trials with high dose bical utamide, 34 of 36 evaluable patients had PSA 
declines by a median of 96.5% and these nadirs were achieved within the first 4 weeks of 
treatment ( 10). We would expect similar if not better results with enzalutamide.  Therefore, a
clinical trial in this population is  ethical and appropriate.  The NC I has conducted several trials in 
this population previously.  
This population will also offer unique opportuni ty to evaluate the independent impact (in 
the absence of ADT) of enzalutamide on both PS A as well as the immune system.  Much like 
previous studies with high-dose bicalutamide in this population, s imilar trials are likely to be 
done to see if disease control with enzalutamide is possible in nmCSPC, with less side effects 
relative to ADT ( 10).
Given the previous experience with high dose bicalutamide in this population, a study 
with time to progression as an end point with c ontinuous enzalutamide would be expected to take 
well over 2 years ( 10).  We feel that using a short course of enzalutamide therapy of 3 months we 
can assess the immunologic impact and determine the impact of vaccine on tumor re-growth 
rates.  Therefore, for practical considerations (number of patients required and length of time to conduct the trial with a clinical progressi on endpoint) this trial will be conducted over a
minimum of 6-12 months, including a 3 month course of therapy of enzalutamide.
This proposed brief 3 month enza lutamide course of therapy is consistent with a standard 
approach of intermittent ADT ( 36,37).  In the intermittent ADT approach in nmCSPC, one or 
two doses of ADT are given and then PSA is followed for recovery at which time subsequent ADT dosing is considered.  The same intermittent strategy will be done in this trial, substituting enzalutamide for ADT.  Furthermore, this popula tion allows for the unique opportunity to follow 
PSA/tumor re-growth rate/recovery once a standard therapy is discontinued.  Consistent with 
common clinical practice no immediate re-treatment will be required in the months following discontinuation of enzalutamide.  Patients would be started on ADT as clinically appropriate, as 
suggested by their PSA doubling time.  
1.2.8 The Importance of Evaluating the Immunologic Response
Our group at in the LTIB has previously ev aluated immunologic parameters in clinical 
trials with PSA-TRICOM among several immunothe rapy studies.  A previous trial in mCRPC 
patients with PSA-TRICOM alone suggested that patients with greatest magnitude of T-cell-
specific response against PSA had favorable clinical outcomes ( 21).  That same trial also 
suggested that changes in regulatory T-cell function were also associated with improved clinical 
outcomes ( 38).  While the these findings are not surrogate markers of response, they have 
improved our knowledge of a va ccine-generated immune res ponse and provided a better 
understanding of what factors are potentially important in mounting a sufficient anti-tumor 
immune response that could be associated with improved clinical outcomes.  These and other data have allowed us to optimize vaccines in subsequent clinical trials.
Similarly, immunologic paramete rs will be valuable in unde rstanding the benefits of 
PSA-TRICOM with enzalutamide.  Are the same a ssociations seen or other changes in natural 
killer cells or cytokines of greater importance in this combination?  Furthermore, baseline 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
19immune characteristics will be evaluated to determine if they have the potential to predict 
responders or likely non-responders to immune comb inations.  While this hypothesis generating 
data would have to be prospectively evaluated in future clinical trials, it may improve our 
understanding about how best to deploy vaccines in combination with enzalutamide and other forms of hormonal therapy.  If enzalutamide increases naïve T-cell production from the thymus as suggested by the pre-clinical data, this ma y have important ramifi cations in the timing of 
vaccine in future clinical trials. This and other data may also provide information early on in the 
therapeutic regimen about which patients would benef it from continued vaccine in combination 
with enzalutamide. 
It will also be of great importance to understand what the immunologic impact is of 
enzalutamide alone.  New data from commonly used cytotoxic agents has suggested that some chemotherapy agents can enhanc e anti-tumor immune responses (34, 39).  With this new 
understanding, clinical trials are be ing design to exploit this aspect of these respective therapies.  
Enzalutamide and other modern androgen receptor-targeting agents will be the mainstay of prostate cancer therapy for the foreseeable future.  Future trials are likely to evaluate 
enzalutamide monotherapy in men with nmCSPC and this trial will be ab le to evaluate the 
specific immunologic impact of enzalutamide in men with normal testoste rone levels.  With 
sipuleucel-T already approved and ipilimumab and PSA-TRICOM in phase III testing, it is likely 
that immunologic optimization will be  important in the future trea tments of prostate cancer.  Few 
groups are as well positioned and have the experience as the LTIB to conduct this rigorous immune testing from clinical samples of patients treated with enzalutamide to gain a better understanding about its  immune properties. 
1.2.9 Change in regrowth rate as endpoint
Although vaccines have improved overall survival  in mCRPC, they have not been shown 
to change short term TTP when used as monothe rapy.  Interestingly, similar findings were also 
seen with ipilumimab in melanoma ( 40).  Although this is not what is customarily seen with 
cancer treatments, it may be a characteristic of modern immune therapeutics ( 41).  An emerging 
mechanism to evaluate tumor growth rates using mathematical models may provide additional insight into this phenomenon( 42,43).    In a recent review of 5 NCI mCRPC trials including a 
vaccine trial, there appeared to be a sustained decrease in tumor growth rate in vaccine patients as compared to those treated with chemotherapy , who had transient reductions in tumor size, but 
then growth rate resumed at the same pre-treatment rate once cytotoxic therapy was discontinued. ( 44) This data suggests that a vaccine i nduced immune response may not decrease 
tumor size (or change TTP) but may lead to a ltered tumor growth rates which could have more 
substantial impact on overall survival ( 41). (See Figure 9)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
20Figure 8 . PSA-TRICOM can affect growth rate in 80 days.  An analysis of the ECOG trial 9802, 
which treated castration-sensitive non-metastatic prostate cancer patients (n=29) suggests PSA-
TRICOM alters tumor growth rate, as measured by PSA (log g (growth rate) +/- SE (standard 
error)), within 80 to100 days. (45)This retrospective analysis used the tumor growth rate equation 
(44)determined that by day 80 after PSA-TRICOM therapy was initiated a statistically significant 
change in tumor growth rate was detectable compared to baseline.  This altered growth rate was 
sustained at day 100 as well.  These data supports the hypothesis that vaccines exert their therapeutic 
effect not by reducing tumor burden, but by altering tumor growth rate. 
Furthermore, unpublished data from an EC OG PSA-TRICOM trial in non-metastatic 
prostate cancer demonstrated a reduced growth  rate within 100 days of vaccine initiation ( 45).
(Figure 8 ) Similarly, Sipuleucel-T has significantly  prolonged PSA doubling time (another way 
to measure growth rate) after initial hormona l therapy in the same patient population ( 46).
Together, these data suggest that vaccine can  impact growth rate in the nmCSPC population 
within 80 to 100 days.  Furthermore, for patients getting combination therapy, disease can be 
controlled by standard therapies in the short term, while vaccines may impact tumor re-growth rates in the long term, ultimately resulting in prolonged TTP compared to standard therapy alone, (Figure 10).
This trial will provide an opportunity to pr ospectively define the mechanism by which 
vaccines in combination with standard therapies ca n result in TTP benefit compared to that same 
standard therapy alone.  By discontinuing the enzalutamide after 3 months and allowing PSA 
values to recover to baseline, we will have the opportunity to determine if a vaccine-mediated 
immune response can alter that tumor re-growth rate .  As demonstrated by Drs. Fojo and Stein 
previously, 80-100 days is sufficient time to calc ulate a meaningful change in growth rate in 
patients with nmCSPC. (Figure 8 )
If this study can prospectively demonstrat e a difference, measured by one standard 
deviation in tumor re-growth rate, it would pr ovide an important proof of concept for the 
mechanism by which vaccines may improve standard therapies.  Furthermore, it would better define the potential role of vaccines (as part of a therapeutic combination) in the treatment of prostate cancer and other malignancies.

Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
211.2.10 Tumor Growth Kinetics
1.2.10.1 The regression-growth equation
Drs. Stein and Fojo at the NCI have developed an equation based on  the assumption that 
the change of a tumor's quantity during therapy results from 2 independent component processes: 
an exponential (first-order kinetics)  decrease/regression and an exponential regrowth of the tumor. 
(44) The equation is f(t) = exp(-d * t)+exp(g * t) - 1 (A) where exp is the base of the natural 
logarithm, e= 2.7182, and f(t) is the tumor (or in MTC calcitonin) measurement at time tin days, 
normalized to (divided by) the tumor measurement at day 0, the time at which treatment is 
commenced. Rate constant d(decay, in daysí) represents the exponential decrease/regression of 
the serum tumor marker (i.e. PSA) signal during therapy. Rate constant g(growth, also in daysí)
represents the exponential growth/regrowth of th e tumor during treatment. These rate constants 
may be expressed in terms of ha lf-lives and doubling times. Thus, dequals ln 2(0.693) divided by 
the time it takes for the regressing part to shrink by half, whereas g equals ln 2divided by the time 
for the growing component to double. ( 44)
Two earlier papers depict theoretical curves de picting the separate components of Equation 
(A) and how these combine together to give  the time dependence of the tumor size,  f.(44)
When the data showed a continuous decrease from  the time of treatment start, so that only the 
regression parameter dwas found to differ significantly from zero with P< 0.05, Equation (A) 
was replaced by the following reduced form, with the growth rate constant eliminated: f(t) = 
exp(-d * t ) (B) When tumor measurements showed a continuous increase, so that only the growth 
parameter gwas found to differ significantly from zero with P< 0.05, Equation (A) was replaced 
by the following reduced form, with the decay constant eliminated: f(t) = exp(g *t) .
1.2.10.2 Data Analysis  
For each patient an attempt to fit Equation (A) to each data set for which more than one 
data point is available. Curve fitting will be performed using Sigmaplot (Systat Software), or by 
using the Solver routine in an Excel spreadsheet. We will extract parameters g and d with their associated Student's t and P values. ( 44) Data will be analyzed in Excel (Microsoft) and in 
Sigmaplot 9.0. Linear regressions to evaluate the relationship between the growth rate constant, g,
or other parameters will be imp lemented using the polynomial li near routine of Sigmaplot 9.0. 
Sample comparisons were performed by Student's t-test, using SigmaStat 3.5 (Systat Software), 
with Pset at 0.05 for significance. ( 44)
Figure 9 .  Enhanced Efficacy with Enzalutamide.  
Enzalutamide has greater androgen receptor (AR) binding 
affinity and a greater negative impact on AR nuclear import than bicalutamide with Dihydrotestosterone (DHT) as a control.  In addition with enzalutamide there is no AR binding with the DNA and coac tivatior receruitment.  (2)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
221.2.11 Rationale for Re-Treatment  of Patients with a Sec ond Course of Enzalutamide
As previously stated, there is no standard of car e for patients with nmCSPC.   Given that 20-40% 
of patients diagnosed each year with prosta te cancer (over 250,000 men in the US alone) have 
recurrent disease after definitive therapy, this  makes up a large population of patients.  The 
standard of care for patients with nmCSPC includes ADT and active surveillance.  Generally,
these patients can be followed without therapy until their PSA doubling time escalates at which 
time ADT is often started.  ADT can be given co ntinuously or intermittently, i.e. 2-3 doses of 
ADT to suppress PSA, and then allow for PSA re covery.  Once PSA has recovered ADT can be 
resumed for an intermittent basis based on PSA metrics and continued castration sensitive disease.  A large study of intermittent vs. c ontinuous ADT in this population of patients has 
demonstrated that intermittent ADT was non-infe rior to continuous ADT in terms of overall 
survival.  Also there were improvements in quality of life factors in patients treated with intermittent ADT. 
49
Given that this trial will explore the short term benefits of a brief course of enzalutamide for 3 
months, it may be prudent to evaluate if this treatment could be given for a second course and 
induce a second, sustained PSA decline.  From a broad prostate cancer perspective, this would be 
valuable information moving forward if future larger trials would be considered to evaluate
enzalutamide as possible alternative form of intermittent anti-androgen therapy.  Such a therapy may be preferred over (intermittent) ADT from a quality of life perspective. 
1.2.12 Rationale for Evaluating Changes in Te stosterone and Rela ted Hormone Levels
Enzalutamide, an androgen receptor inhibitor,  differs from traditional androgen deprivation 
therapy in its ability to inhibit the androgen re ceptor without lowering testosterone and is 
associated with an overall increase in testoste rone levels. Consequently , enzalutamide and other 
non-steroidal antiandrogens have a different side effect profile. A recent European study 
evaluated Enzalutamide monotherapy in hormone-naïve prostate cancer, and examined a series 
of hormone levels at various time points in administration to determine changes in testosterone and testosterone related hormones.
50While they found increased levels  of testosterone, estradiol, 
and luteinizing hormone, levels were checked until the 25 week time point and only once thereafter. 
We seek to further elucidate this mechanism of  action by obtaining hormone levels at each 
follow up visit, as well as pre-Enzalutamide,  1 hour post, 24 hours post, 48 hours post, and 72 
hours post administration, when logistically feasible .  Dr. Doug Figg’s lab is currently evaluating 
a murine model to demonstrate the presence of androgen receptors in the hypothalamus which 
may influence the levels of testos terone and relate d hormones in the serum. This pre-clinical data 
can also be correlated with clinical informatics that will be obtained with these serial hormonal levels.
1.2.12.1 Evaluating Immunologic Effects of Low Dose EnzalutamidePatients from the arm receiving enzalutamide al one (160 mg daily for 84 days, without ADT) 
have been assessed for immunologic impact from cohort 1. Peripheral blood mononuclear cells 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
23(PBMCs) collected from 12 patients pre and pos t enzalutamide (days 14, 28, 84, and 100) were
analyzed by flow cytometry to identify 123 imm une cell subsets, including 9 standard subsets 
(CD4+ and CD8+ T cells, T-regulatory cells (T reg), B cells, conventional and plasmacytoid 
dendritic cells (cDC, pDC), natural killer cells (NK), natural killer T cells (NKT), and myeloid 
derived suppressor cell (MDSC)), and 114 subset s relating to maturati on and function. PBMCs 
were also assessed for TREC to identify rece nt thymic emigrants, and by microarray to 
determine changes in global gene expression.  
Treatment with enzalutamide induced several notable alterations in peripheral immune cells, 
suggesting that it has potential immune activating properties. These changes occurred early following treatment, and included an increase of  NK cells, decreased frequencies of MDSCs 
with a suppressive phenotype (e.g. PD-L1+ MDSC, gMDSC, and CD16+ MDSC), and decreased 
frequencies of both CD4+ and CD8+ T-lymphocytes expressi ng the immune inhibitory 
checkpoint molecule CTLA4. 
Additionally, treatment with enzalutamide increas ed TREC levels by >75% in 7 out of 12 
patients compared to pre-therapy levels (p= 0.012); naïve CD4+and CD8+ T-lymphocytes were 
also elevated by >25% in those patients dem onstrating the greatest increase in TREC. Gene
expression analysis of PBMCs corroborated these findings, showing that enzalutamide increased 
activation of interferon-gamma signalingand related immune activating pathways.
These preliminary findings demonstrate that short-course enzalutamide has immune activating 
properties in cancer patients,  and support the combination of  enzalutamide with immunotherapy.
Since the immunologic effects are likely separate from just blocking AR (based on preclinical 
data serving as the rationale for this study)  it would be prudent to explore the immunologic 
impact of lower doses of enzalutamide (i.e. 80 mg) to determine if the immune impact is preserved, while also limiting the toxicity seen with enzalutamide alone at 160 mg/day.  Although enzalutamide is well tole rated, fatigue and breast tendern ess in men were frequently 
seen and could limit its use (independent of ADT) as an immune adjuvant.  It is likely these side effects can be minimized at a lower dose.  If this can be accomplished at a lower dose, it is more likely to lead to the use of enzalutamide as a possible immunologic adjuvant in other diseases 
where immune therapies are now approved includi ng lung cancer, bladder cancer, melanoma, 
and renal cancer.
We planned a study to explore the immunologic ef fects in biochemically recurrent prostate 
cancer of enzalutamide 80 mg/day for 3 months.  The data were to have been compared against 
the existing immune data descri bed above with enzalutamide at 160 mg/day for 3 months,
however this cohort was closed before enrollment due to lack of patient interest in participation
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT
2.1 E
LIGIBILITY CRITERIA
2.1.1 Inclusion Criteria
A. Histopathological documentation of prostate cancer confirmed in the 
Laboratory of Pathology at the National Institutes of Health (NIH) Clinical 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
24Center, or Walter Reed National Military Medical Center prior to enrollment. 
If no pathologic specimen is available, patients may enroll with a pathologist’s report showing a histologic diagnosis of prostate cancer and a clinical course consistent with the disease. 
B.  Biochemical progression defined as follows:
xFor patients following definitive radiation therapy: DULVHLQ36$RI
ng/mL above the nadir (per RT OG-ASTRO consensus criteria). 
xFor patients following radical prostatectomy: rising PSA after surgical 
procedure. (Patients must have a PSA >2ng/ml)
C.  ECOG performance status of 0–1 (Karnofsky >80%, see Appendix A ).
D. Patients must have a PSA doub ling time of 12 months or less.
E.  Patients must have a rising PSA as confirmed by 3 values done at least 1 week 
apart and over no less than 1 month.
F.  Recovery from acute toxicity related to prior therapy, including surgery and 
UDGLDWLRQRUQRWR[LFLW\JUDGH
G. Negative CT scan/MRI and bone scan  for metastatic prostate cancer.
H. Hematological eligibility parameters (within 16 days before starting therapy; 
see Appendix D ):
x*UDQXORF\WHFRXQW 000/mm3
x3ODWHOHWFRXQWPP3
x+JE g/dL
I. Biochemical eligibility parameters (within 16 days before starting therapy):
x+HSDWLFIXQFWLRQE LOLUXELQPJG/25LQSDWLHQWVZLWK
*LOEHUW¶VV\QGURPHDWRWDO ELOLUXELQ$67DQG$/7 
times upper limit of normal.
J. No other active malignancies within the past 36 months (with the exception of 
nonmelanoma skin cancers or carcinoma in situ of the bladder) or life-
threatening illnesses
K.   Willing to travel to the NIH for follow-up visits.
L. 18 years of age or older. M. Able to understand and sign informed consent.N.%DVHOLQHWHVWRVWHURQHORZHUOLPLWRIQRUPDO.
O.36$QJP/
P. The effects of enzalutamide, PSA-TRICOM or the combination on the developing human fetus are unknown. For this reason, men must agree to use adequate contraception (horm onal or barrier method of birth control; abstinence) 
prior to study entry and for the duration of study participation.  Should a woman 
become pregnant or suspect she is pregna nt while her partner is participating in 
this study, she should inform her treating physician immediately.
2.1.2 Exclusion Criteria
A. Immunocompromised status due to:
xHuman immunodeficiency virus (HIV) positivity.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
25xActive autoimmune diseases such as Addison's disease, Hashimoto's 
thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, 
myasthenia gravis, Goodpasture syndrome or active Grave's disease. Patients with a history of autoimmuni ty that has not required systemic 
immunosuppressive therapy or does not threaten vital organ function including CNS, heart, lungs, kidneys, skin, and GI tract will be allowed.
xOther immunodeficiency diseases
B. Chronic administration (defined as dail y or every other day for continued use 
> 14 days) of corticosteroids deemed systemic by investigator within 28 days before the first planned dose of PSA-TRI COM. Use of inhaled steroids, nasal 
sprays, and topical creams for small body areas is allowed.
C. Serious intercurrent medical illness that, in the judgment of the investigator,
would interfere with patient’s ability to carry out the treatment program.
D. History of seizure, including any febr ile seizure, loss of  consciousness, or 
transient ischemic attack, or any cond ition that may pre-dispose to seizure 
(e.g., prior stroke, brain arteriovenous ma lformation, head trauma with loss of 
consciousness requiring  hospitalization).
E. Other medications used for urinary symptoms including 5-alpha reductase 
inhibitors (finasteride an d dutasteride) and alterna tive medications known to 
alter PSA (eg phytoestro gens and saw palmetto)
F. History of prior chemotherapy G. History of prior immunotherapy within the last 3 yearsH. Major surgery within 4 weeks prior to enrollment (Day 1 visit).I. History of allergic reac tions attributed to compounds of similar chemical or 
biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia 
vaccine)
J. Known allergy to eggs, egg product s, aminoglycoside antibiotics (for 
example, gentamicin or tobramycin).
K. History of atopic dermatitis or ac tive skin condition (acute, chronic, 
exfoliative) that disrupts the epidermis
L. Previous serious adverse reactions to smallpox vaccinationM. Unable to avoid close contact or household contact with the following high-
ULVNLQGLYLGXDOVIRUWKUHHZHHN VDIWHUWKH'D\YDFFLQDWLRQ DFKLOGUHQ
years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, or (d) immunocompromised individuals, such as those with HIV.
N. Receipt of an investigational agent within 30 days (or 60 days for an antibody-
based therapy) before the first planned dose of study drugs.
O. Patients who test positive for HBV or HCVP. Use of herbal products that may decr ease PSA levels (e.g. saw palmetto)  
Q. Any gastrointestinal disease that c ould hinder the absorption of enzalutamide
R. Uncontrolled hypertension (SBP>170/ DBP>105)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
262.1.3 Recruitment Strategies
This study will be listed on available websites ( www.clinicaltrials.gov ,
https://ccr.cancer.gov/clinical-trials-search-start ) and participants will be recruited from the 
current patient population at NIH.
2.2 S CREENING EVALUATION
A. Pathological confirmation of diagnosis by the Laboratory of Pathology, CC, NIH, or 
Walter Reed National Military Medical Center (if specimen is available) may be 
obtained anytime prior to enrollment.
B. The following parameters will be obtained within 8 weeks prior to start of enrollment:
1. HIV test2. Hepatitis B and C3. Tc-99 whole-body scintigraphy4. CT (or MRI may be substituted at investigator’s discretion) of chest, abdomen 
and pelvis
2.3 R
EGISTRATION PROCEDURES 
Authorized staff must register an eligible ca ndidate with NCI Central Registration Office (CRO) 
within 24 hours of receiving a signed consent. A registration Eligibility Checklist from the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Central Registration Office ncicentralregistration-l@mail.nih.gov .
After confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol prior to the release of any 
investigational agents. When relevant, treatment assignment is c onveyed to the Pharmacy at the 
same time. Verification of Registration will be forwarded electronically via e-mail to the research team. A recorder is available during non-working hours.
2.4 T
REATMENT ASSIGNMENT AND RANDOMIZATION /STRATIFICATION PROCEDURES
Cohorts
Number Name Description
1 Cohort 1 Patients with nonmetastatic castration sensitive prostate cancer 
Arms
Letter Name Description
A Standard dose enzalutamide 
aloneEnzalutamide alone administered at the standard dose (160 mg 
daily)
B Enzalutamide with PSA-
TRICOMStandard dose enzalutamide with concomitant vaccinia-PSA-TRICOM and then fowlpox-vaccine
Stratifications
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
27Name Distinct Options Notes
PSA doubling time less 
than 6 months Yes
No
Randomization and Arm Assignment 
After confirmation of eligibility at Central Registration Office (CRO ), patients in cohort 1 will be 
randomized on a 1:1 basis between arms A and B, stratifying for PSA doubling time using acomputerized randomization process.
CRO staff will send a secured e-mail to Principal Investigator and research nurse with the 
Verification of Registration of th e patient and treatment arm patient is randomized. This process 
will be completed within 15–30 minutes  of faxing the eligibility checklist. CRO will keep track of 
all randomization data in Clinical Data Registry (CDR) of CRO. 
2.5 B
ASELINE EVALUATION
A. Baseline electrocardiogram (EKG) on all patients, and appropr iate cardiologic 
evaluation, as clinically indicated, to provide baseline function and identify any 
patients who should be monitored closely fo r cardiac risks associ ated with vaccinia 
vaccination
B. Apheresis (cohort 1 only)
C. The following parameters will be obtained within 16 days prior to start of treatment:
1. Clinical evaluation
xHistory and physical examination 
xECOG performance status (see Appendix A )
xHeight, weight
2. Laboratory studies
xSerum PSA 
xCBC/differential, with platelet count
xSerum testoste rone level
xSerum chemistries (Na+, K+, Cl-, CO 2, glucose, BUN, creatinine, 
albumin, calcium, magnesium, phosphorus, alkaline phosphatase, 
ALT, AST, total bilirubin, LDH, CK, uric acid, total protein)
xLymphocyte phenotyping CD3/CD4/CD8
3 STUDY IMPLEMENTATION
3.1 S TUDY DESIGN 
xThis is a randomized Pilot trial of enzalu tamide vs. enzalutamide and PSA-TRICOM in 
patients with nmCSPC prostate cancer. Thirty-four patients will be enrolled.  
xEnzalutamide will be given at the standard dose of 160 mg daily for 3 months (7).  
PSA-TRICOM will be administered identical to the Phase III dosing with vaccine 
given week 1 (vaccinia-PSA-TRICOM, 2x108infectious units subcutaneously) and 
then fowlpox-vaccine (1x109infectious units subcutaneously) on weeks 3 and 5
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
28followed by monthly fowlpox-vaccine (1x109 infectious units subcutaneously) for a 
total of 5 months (including vaccinia, vaccine is administered over 6 months).
xPatients will be followed for PSA recovery after enzalutamide has been discontinued.  
Patients who do not develop a 25% decline in PSA after 3 months will not be evaluated 
for tumor re-growth and additional patients will be enrolled to evaluate for that endpoint.
xPatients who have been on study for at  least 7 months without PSA equaling or 
exceeding the value at study entry, and whose PSA subsequently (beyond 7 months) 
returns to or exceeds the value at study entry, may be retreated with a 3-month course of Enzalutamide. 
xPatients who continue to be followed for rising PSA af ter completing either one or 2 
courses of enzalutamide but have not required ADT may be  followed after treatment.  
Such visits may occur at 4 week intervals based on logistics and clinical parameters (i.e. PSA velocity) once pa tients have exceeded their baseline PSA value. This 
approach is consistent with the clinical management of such non-metastatic  patients 
(rising PSA and not on ADT.)
xThe primary endpoint of this trial will be a comparison of the tumor re-growth rates at 
7 months. This time frame should be suffici ent to evaluate immune effect on the re-
growth rate given that the ECOG 9802 analysis demonstrated a significant change in tumor growth rate after starting PSA-TRICOM.Secondary endpoints include growth rate at  points other than 7 months, toxicity, 
immunologic responses to vaccine with en zalutamide and to enzalutamide alone in 
men with normal testos terone, and response to second course of enzalutamide.  When 
possible, patients will be followed for TTP. End of study period will be 12 months in each arm (24 months if patients are eligible and elect to receive a 2
ndcourse of 
enzalutamide).
xPreliminary data from the first cohort of ra ndomized patients suggests that enzalutamide 
alone can induce an immunologic response.  A second cohort of 15 patients will explore a 
lower dose of enzalutamide at 80 mg to de termine if similar immunol ogic responses can 
also be seen at a lower dose, where toxicity is less likely.
3.1.1 Protocol Stopping Rules
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) version 
4.0 for grading systemic toxicity (see section 6.3).
xOne occurrence of grade 5 toxicity by th e NCI-CTCAE version 4.0 attributable to 
the treatment regimen.
xTwo occurrences of grade 4 toxicity by the NCI-CTCAE version 4.0 attributable to 
the treatment regimen.
If either of the above occurs, the Principal Investigator will halt accrual to the trial and will 
discuss with the NCI Institutional Review Boar d (IRB) and Medivation and Astellas Inc. whether 
any changes need to be made to the protocol.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
29All patients will receive vaccine treatments at the NIH Clinical Center, patients will receive 
enzalutamide primarily in the NCI outpatient setting.
We estimate an accrual of approximately 2 patients per month, with full accrual of 34 patients 
within 18 months.
3.2 D RUG ADMINISTRATION
All patients in cohort 1 (n=34)  will receive enzalutamide 160 mg daily orally for 3 months. 
Patients randomized to vaccine arm (Arm B) w ill receive PSA-TRICOM identical to Phase III 
dosing, which consists of a single immunization of PROSTVAC-V (vaccinia-PSA-TRICOM, 
2x108infectious units subcutaneously) in Week 1, followed by immunizations of PROSTVAC-F
(fowlpox-PSA-TRICOM 1x109infectious units subcutaneously) administered in Weeks 3, 5, 9,
13, 17, and 21.  
3.3 T REATMENT MODIFICATIONS
3.3.1 Vaccine
3.3.1.1 Dosing delay
x3DWLHQWVPXVWKDYHUHFRYHUHGWRJUDGHWR[LFLW\UHODWHGWRY DFFLQHIRUWKH
parameters used to assess levels of organ function required for eligibility (see 
Section 2.1.1) after each vaccination in  order to receive a subsequent 
vaccination.  
x3DWLHQWVZLWKJUDGH WR[LFLW\QRWUHODWHGWRYDFFLQHWUHDWPH QWLH attributed to 
enzalutamide) will remain eligible to receive vaccine.  
xPatients that recover from > grade 2 toxicity unrelated to vaccine treatment (i.e. 
related to enzalutamide) may remain eligible for the vaccine.  
x,IJUDGHQRQDXWRLPPXQHWR[LFLW \DWWULEXWDEOHWRWKHYDFFLQH SHUVLVWVIRU!42
days, the patient will not receive furt her vaccine inoculations and will be 
removed from the protocol treatment and followed for resolution of toxicity and immune endpoints.  
xPatients who develop grade 3 injection site reactions will have their vaccine held 
until injection site reaction resolves to grade 2 or less.
x3DWLHQWVZKRGHYHORSDJUD GHDOOHUJLFRUDXWRLPPXQ e disease that threatens 
YLWDORUJDQIXQFWLRQRUDQ\JUDGHDXWRLPPXQLW\QRWUHODWHGWRDWKHUDSHXWLF
response, will be removed from the pr otocol treatment and followed for 
resolution of toxicity and immune endpoints.  
xPatients who develop any grade 4 toxicity attributable to the study drug(s) will be 
removed from the protocol treatment and followed for resolution of toxicity and immune endpoints.
xIf a scheduled vaccine dose is missed due to scheduling or logistical issues, the 
vaccine may be given within 7 days of the appointed time
3.3.1.2 Dose modifications
No dose modifications are allowed with this vaccine.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
303.3.2 Enzalutamide
,IDSDWLHQWH[SHULH QFHVD*UDGHQRQ -hematologic toxicity attributable to enzalutamide or an 
intolerable side effect attributable to enza lutamide, withhold dosing for one week or until 
V\PSWRPVLPSURYHWR*UDGHWKH QUHVXPHDWWKHVDPHGRVHLI FOLQically appropriate.  If 
toxicity recurs enzaluatmide will be held again using the above parameters or discontinued at the 
discretion of the investigator.
Patients who develop any grade 4 toxicity attributable to the study drug(s) will be removed from 
the protocol treatment and followed for resolution of toxicity and immune endpoints.
3.4 P ROTOCOL EVALUATION (SEEAPPENDIX C)
3.4.1 All patients who are deemed eligible and who sign an info rmed consent will be enrolled 
in this trial.
3.4.2 A complete history and physical examina tion, including ECOG perfo rmance status, will 
be done within 16 days before enrollment.  
3.4.3 Laboratory Studies 
(See also Appendix C )
xSerum PSA 
xCBC/differential with platelet count
xSerum testoste rone level
xSerum chemistries (Na+, K+, Cl-, CO 2, glucose, BUN, creatin ine, albumin, calcium, 
magnesium, phosphorus, alkaline phosphatase, ALT, AST, total bilirubin, LDH, CK, 
uric acid, total protein)
xHIV/Hepatitis B/Hepatitis C tests (within 8 weeks prior to start of enrollment)
xLymphocyte phenotyping CD3/CD4/CD8
xPAP (prostatic acid phosphatase)
xThe following serum hormone levels will be drawn at each follow up visit after 
enrollment and pre-Enzalutamide administration, and 1 hour post, 24 hours post, 48 
hours post, and 72 hours post administration, when logistically feasible.
otestosterone 
odihydrotestosterone (DHT)
osex hormone-binding globulin (SHBG)
odehydroepiandrosterone (DHEA)
oluteinizing hormone (LH)
ofollicle-stimulating hormone (FSH)
oandrostenedione
oprolactin 
oestradiol 
xPlasma VEGF levels will be drawn at the st art and at the end of each patient’s second 
12-week course of Enzalutamide. 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
313.4.4 Radiographic assessment 
Patients will not undergo scheduled  radiographic assessment fo r metastatic disease unless 
clinically indicated for increasing PSA or symp toms. Radiologic studies consisting of bone scan, 
CT scan of chest, and CT scan of abdomen/p elvis will be performed at baseline. MRI may be 
substituted for CT scan at the discretion of the investigator.
Patients will undergo a radiographic assessment with CT scan of chest, abdomen, and pelvis and 
bone scan once PSA returns to baseline at study entry or higher.  These scans will be obtained 
prior to retreatment with a 3- month course of enzalutamide. 
For patients who are eligible and elect to receive a second course of enzalutamide therapy for 3 
months, re-staging CT scan of chest, abdom en, and pelvis and bone scan will again be done 
when PSA reaches baseline.
3.4.5 Assessment for PSA-TRICO M administration (Arm B)
Dosing and administration of PSA-TRICOM will be performed in the Day Hospital.  Patients 
will be monitored with vital sign s (blood pressure, heart rate, resp iratory rate, temperature) prior 
to and within 1 hour after the initial vaccine treatment. On subse quent visits (where rF-PSA-
TRICOM is administered) patients will have vital signs checked prior to vaccine and then be monitored for 30 minutes after vacci ne treatments.  (Post-vaccine vital signs will not be required 
except for the first vaccination.) Documentation of any patient reported symptoms occurring 
between dosing will be included in  the assessment.  Laboratory assessments will be conducted as 
perAppendix C : On Study and Follow-Up Evaluations .
3.5 C
ONCURRENT THERAPIES 
Concurrent hormonal therapy not otherwise stipulated in the protocol will not be allowed. Concurrent anticancer treatment with chemothe rapy, systemic glucoc orticoids (topical and 
inhaled steroids allowed), radia tion therapy, major surgical procedures for prostate cancer, and 
nonprotocol-related immunothera py will not be permitted.
3.6 C
RITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFFSTUDY CRITERIA
Prior to removal from study, effort must be made  to have all subjects complete a safety visit 
approximately 30 days following the last dose of study therapy.
3.6.1 Criteria for removal from protocol therapyPatients will be removed from treatment for the following:
xClinical or radiographi c progression of disease.
xGrade 3 or greater toxicity attributed to treatment that does not resolve to grade 1 within 
42 days from time of scheduled treatment.
xGrade 3 or greater toxicity not related to treatment that does not resolve to grade 2 within 
42 days from time of scheduled treatment.
xGrade 2 or greater autoimmune disease that threatens vitals organs.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
32xAny Grade 4 toxicity that is possibly, probab ly or definitely rela ted to the protocol 
treatment will require a pa tient to be off-treatment
xIntercurrent illness or medical circumstances. If at any time the constraints of this 
protocol are detrimental to the patient’s hea lth, the patient may be removed from protocol 
therapy and reasons for withdrawal will be documented.
xAny grade of seizure will require a patient to be off-treatment.
xRequirement for androgen deprivation therapy
xCompletion of protocol therapy 
3.6.2 Off-Study Criteria
xPatient is off-treatment and has agreed to be followed on a long term therapy protocol as 
outlined in section 3.7
xPatient requests to be taken off study. Reasons for withdrawal will be documented.
xNoncompliance with protocol guidelines (p atient removed at di scretion of Principal 
Investigator).
xDeath
3.6.3 Off Protocol Therapy and Off-Study Procedure
Authorized staff must notify Central Registrati on Office (CRO) when a subject is taken off
protocol therapy and when a subject is taken off study. A Participant Status Update Form from 
the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted email to:  NCI Central Registration Office 
ncicentralregistration-l@mail.nih.gov.
3.7 P OST-STUDY EVALUATION (FOLLOW -UP)
The Biologic Response Modifiers Advisory Committee has recommended that long-term follow-up extend over a period of 15 years. Information re garding the findings will be reported to the 
FDA. Patients randomized to receive PSA-TRICOM will be offered enrollment in the 04-C-0274“Follow-Up Study of Subjects Previously Enro lled in Immunotherapy Studies Utilizing Gene 
Transfer or other immunotherapeutic agents” once off study.
4 BIOSPECIMEN COLLECTION
4.1 C
ORRELATIVE STUDIES FOR RESEARCH
4.1.1 Immunologic Parameters
xIFN-gamma ELISPOT assay for PSA-specific T lymphocytes (HLA-A2 patients 
only)
xAntibodies to PSA, vaccinia, fowlpox may be tested
xLeukocyte CD3, CD4, CD8 subsets; CD4:CD8 ratio will be drawn at baseline and 
monthly prior to vaccination while the patient remains on trial.
xThe results of the HIV antibody need to be available before treatment to determine 
eligibility
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
33xHLA class I expression (HLA typing) with A2 subtyping (obtain anytime prior to 
enrollment).  Patients may refuse or test may be omitted for logistical purposes 
at the discretion of the investigator.
xAdditional studies will include but are not limited to quantitative and qualitative 
assessments of regulatory T-cells, Natural Killers cells, Myeloid Derived Suppressor Cells, anti-glycan antibodi es and Naïve T-cell/new thymic 
emigrants. 
xAssessment of leve ls of cytokines.
xImmunologic studies will be repeated more frequently if clinically indicated, and 
any abnormalities potentially related to treatment w ill be followed until they 
have resolved, or have been determined not to be treatment-related.
4.1.2 Collection of Research (Immunologic) Blood Samples
Immunologic blood samples will be obt ained via apheresis when logis tically feasible at Baseline
(prior to treatment), after 3 months and after 6 months in all HLA-A2 patients. (Additional 
apheresis could be considered at  the discretion of the investigat or and with the consent of the 
patient.)  We plan to examine the immune response in selected patients (HLA-A2 positive) when feasible and if patients consent. (The HLA-A2 requirement is based on the ability to assess immune response in these patients using immunologic response techniques (ELISPOT).  This analysis is not limited to these patients due to any reason to believe that non-HLA-A2 will not have an immune response, but rather those immune  responses can not be detected by our current 
ELISPOT methods.)
In all patients undergoing apheresis, 5 x 10
8to 2 x 109mononuclear cells will be obtained by a 
single-access (single venipuncture) mononucl ear cell procedure on the Haemonetics V-50
instrument, during which 2.0 liters of whole blood w ould be process at a flow rate of about 70-80
ml/min.  The total duration of the procedure is 90 min to 2 hours.  Patient s will be required to 
have a minimum HCT of 28% and a platelet c ount of at least 75,000 to undergo a Haemonetics 
procedure. Apheresis will allow us to obtain sufficient PBMC samples from patients to be able to perform 
not only the standard Elispot using the PSA-3 peptid e, but to also look at other epitopes that may 
be important in evaluating an antigen cascade effect from the therapy administered. This will allow us to gain important immunologic info rmation to determine if patients are not only 
mounting immune responses to the antigens in th e vaccine, but to also immune responses to 
other antigens present on the tumor cells. At the time points when apheresis is not obtained, we will obtain 6 green top (10ml) tubes. These will be used for ELISPOT assays (as described inAppendix D ). In addition, 2 SST (tiger) top tubes will be drawn for antibody testing (as 
described in Appendix D ). If apheresis is not done, research samples will be obtained per
Appendix C
Blood samples may be used for other research  studies which may include phenotypic and 
functional analysis of immune cell subsets, and analysis for cy tokines, chemokines, antibodies, 
tumor-associated antigens and / or other markers.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
34Immunologic blood samples will be processed at:
Clinical Services Program
NCI Frederick Cancer Research and Development CenterPO Box BFrederick MD 21702301-846-1707On days samples are drawn, Jennifer Bang h at CSP should be notified (phone: [301] 
846-5893; fax [301] 846-6222). She will arrange courier delivery of the specimens to the processing lab.The weekly patient lists of samples drawn will be emailed to Jen Bangh at banghj@mail.nih.gov and Theresa Burks burkst@mail.nih.gov .
4.1.3 Immunologic Assays
4.1.3.1 IFN-gamma ELISPOTWe plan to examine the immune response in se lected patients (HLA-A2-positive). Lymphocytes 
will be separated from heparinized blood using density gradient centrifugation. The lymphocytes 
will then be placed in human AB serum with 10% DMSO and stored in liquid nitrogen. When samples are available from pre- and post-treatment, the ELISPOT assay will be performed. The ELISPOT assay, measuring IFN-gamma produc tion, is used to determine CTL precursor 
frequency to peptides from PSA, PSMA, MUC-1, PSCA, CEA, and PAP in both pre- and post-
vaccination peripheral blood mononuclear cells, as previously described (39-40). Briefly, 96-
well mL HA plates (Millipore Corporation, Bedford, MA) are coated with 100 Pl/well of capture 
MAb against human IFN-gamma at a concentration of 10 Pg/mL for 12h at RT. Plates are 
blocked for 30 min with RPMI 1640 plus 10% human Ab serum 2 x 10
5 PBMC are added to each 
well. PSA-3A pulsed C1R-A2 cells are added into each well as antigen-presenting cells (APC) at an effector:APC ratio of 1:1. Unpulsed C1R-A2 ce lls are used as a negative control. HLA-A2 
binding flu matrix peptide 59-66 is used as a positive peptide control ( 41). We also perform each 
sample with 6 replicates to control for variab ility. In addition, each sample is run with a flu 
peptide control (pre- and post-vaccine) as well as samples from a “normal” control HLA-A2-positive individual with previously determined levels of flu-specific T-cell precursors. Cells are incubated for 24 h and lysed with phosphate-buffered saline (PBS)-Tween (.05%). Biotinylated 
anti IFN-gamma antibody diluted to 2 Pg/mL in PBS-Tween containing 1% bovine serum 
albumin (BSA) is added and incubated overnight in 5% CO
2 at 37qC. Plates are washed 3 times 
and developed with avidin alkaline phosphatase (GIBCO/BRL, Grand Island, NY) for 45 min. 
After washing the plates 3 times, each well is examined for positive dots. This assay will be 
performed in the Laboratory of Tumor Immunolog y and Biology, NCI, NIH. The number of dots 
in each well will be counted by 2 separate investigators in a blinded manner , and the frequency 
of responding cells w ill be determined.  
4.1.3.2 CD4 T Cell Pro liferation Assay
It is planned that all patient s will undergo exploratory analysis of the ability to detect CD4-
positive responses using a whole-protein PSA assay,  as well as a peptide mix with 63 different 
15-mer peptides by ELISPOT and/or ELISA. 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
354.1.3.3 Sera Antibody Analysis
Serum will be stored at -80 degrees Celsius and there will be planned analysis for generation of 
antibodies to PSA, BCG, PAP, PSMA, PSCA, and/or MUC-1.
4.1.3.4 Flow cytometry analysis of thymic emigrant
To determine recent thymic emigrants, flow cytometry analysis will be performed on peripheral 
blood mononuclear cells. Cells will be resuspended in staining buffer (phosphate-buffered saline 
containing 3% fetal bovine seru m) and stained for 30 minutes at 4°C with the combination of 
following antibodies: APC-H7-conjugated an ti-CD4, PE-CY7-conjugated anti-CD3; FITC-
conjugated CD45RA, PE-c onjugated CD31, PerCP-CY5.5- conjugated Ki-67, AF-700-
conjugated-CD197, V450-conjuga ted CD8, APC-conjugated CD 103, V500-conjugated CD27 all 
purchased from BD Pharmingen, San Diego, CA). After that, FoxP3 intra-cellular staining will be performed on the cells stained with anti-CD4 and anti-CD25. They will be fixed and permeabilyzed using a fix/perm kit (eBios cience, San Diego, CA) according to the 
manufacturer’s manual, and will be labeled with FITC-conjugated anti-Foxp3 antibody 
(236A/E7 clone) or its isotype control antibody (e Bioscience). Flow cytometry will be performed 
on a Becton Dickinson LSRII (BD Biosciences) device.
4.1.3.5 Natural Killer (NK) CELLS
The number and phenotype of NK cells will be determined by phenotypic analysis of PMBCs 
stained for CD56, CD3, CD8, a nd CD16 by flow cytometry.
4.1.3.6 Regulatory T Cells
Regulatory T cells have been shown to inhib it the activation and function of T cells that 
participate in antigen-specific imm une responses.  Higher levels of  regulatory T-cells have been 
reported in the peripheral blood m ononuclear cells of patients with se veral types of tumors.  The 
number and phenotype of regulatory T-cells in  peripheral blood mononucl ear cells from patients 
in this study will be determined by 7-color flow cytometry analysis.  Cells will be resuspended in 
staining buffer (phosphate-buffered saline contai ning 3% fetal bovine serum) and stained for 
CD4, CD25, CD127, FoxP3, CTLA-4, CD45RA, and CD8.  The ratios between regulatory T-
cells and CD4 effector cells and the ratios between regulatory T-cells and CD8 Effector cells will also be analyzed.
4.1.4 Additional AssaysBlood samples may be used for additional research studies, which may include phenotypic and 
functional analysis of im mune-cell subsets and analyses for cytokines (IFN- Ȗ,/ -10, IL-12, IL-2,
IL-4, etc.), chemokines, anti bodies, tumor associated antigens, and/or other markers
All samples will be labeled with the following identifier system.  
xPatient’s enrollment #
xTrial number
xPatient’s initials
Example: 01-ABC
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
36These labels are used only to send the samples from the NIH Clinical Center to the NCI
Frederick Central Repository.  The NCI Repository will process all samples, appropriatelydiscard the label on the blood tube, and then store the samples with unique identifiers, to which only NCI study personnel will have the code to link to patient specific clinical information.Samples will be tracked according to Section 4.2.
If there are inadequate samples for analysis beca use of loss or destruction of those samples, the 
PI will report this to the IRB.
4.1.5 Plasma VEGF levelsSerum samples will be collected to measure vascular endothelial growth f actor (VEGF) levels.  
For this purpose, one 6mL EDTA tube will be obtained at baseline (prior to treatment), 1 month, 
3 months, 3.5 months, 4 months, and 6 months.  Th e analysis will be done with assays developed 
on electrochemiluminescence platform that provides ultra-high sensitivity and very large signal dynamic range. These studies will be done by the Molecular Pharmacology Program, under the direction of Dr. Doug Figg. 
Write the collection time on the vacutainer t ube and place the sample on wet ice immediately 
after collection. The sample should be picked up within 1 hour of collection. 
Please e-mail Julie Barnes at Julie.barnes@nih.gov and Paula Carter pcartera@mail.nih.gov at 
least 24 hours before transporting samples (the Friday before is preferred).
For sample pickup, page 102-11964.
For immediate help, call 240-760-6180 (main blood pr ocessing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number).For questions regarding sample processing, c ontact Julie Barnes by e-mail or at 240-760-6044.
4.1.6 Serum Analysis 
Of the sample collected in 4.1.2, de-identified serum may be sent  for analysis of pre-treatment, 
on-treatment, on progression and post-treatment absolute concentr ations of steroids and ratios of 
11BHSD substrates and products with presence of  treatment and the natu re of the clinical 
response to enzalutamide.  The serum samples ma y be sent under an MTA to the laboratory of 
Dr. Nima Sharifi, of the Cleveland C linic Foundation, at the following address:
Michael P. Berk
Cleveland Clinic FoundationLerner Research InstituteCancer Biology, NB4-152111 East 96th StreetCleveland, OH 44106Tel. = 216.445.9752Email = berkm@ccf.org
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
374.2 S TORAGE AND TRACKING OF COLLECTED BLOOD SAMPLES
All data associated with the patient samples is protected by using a secure database. All samples 
drawn at the NIH Clinical Center will be transported to the NCI Frederick Central Repository by couriers.
Samples will be tracked and managed by Central Repository database. All samples will be stored 
in either a - Û&RU -Û&IUHH]HU7KHVHIUHH]HUVDUHORFDWHGDW1&,)UHGHULFN&HQW UDO
Repository in Frederick, Maryland.
American Type Culture Collection (ATCC) manages the NCI Frederick Central Repositories under subcontract to Leidos Biomedical Research , Inc., Frederick, Inc. NCI Frederick Central 
Repositories store, among other things, biological specimens in support of NIH clinical studies. All specimens are stored in secure, limited-acce ss facilities with sufficient security, backup, and 
emergency support capability and monitoring to ensure long-term integrity of the specimens for research. 
ATCC’s role is limited to clinical research databases and repositories containing patient 
specimens. ATCC does not c onduct or have any vested interest in research on human subjects, 
but does provide services and support the efforts of  its customers, many of which are involved in 
research on human subjects. 
It is the intent and purpose of ATCC to acc ept only de-identified samples and sample 
information. To the limit of our ability, every effort will be made to ensure that protected 
information is not sent el ectronically or by hard copy or on vial labels. 
Sample data is stored in the BioSpecimen Inventory System II (BSI). This inventory tracking 
system is used to manage the storage and retrieval of specimens, as well as to maintain specimen data. BSI is designed for controlled, concurrent access. It provides a real-time, multi-user environment for tracking millions of specimens. The system controls how and in what order database updates and searches are performed. This control prevents deadlocks and race 
conditions. For security, BSI has user password acce ss, 3 types of user access levels, and 36 user 
permissions (levels of access) that can be set to control access to the system functions. BSI provides audit tracking for processes that are done to specimens including shipping, returning to 
inventory, aliquoting, thawing, additives, and other processes. BSI tracks the ancestry of specimens as they are aliquoted, as well as discrepancies and disc repancy resolution for 
specimens received by the repository. If a specimen goes out of the inventory, the system maintains data associated with the withdraw re quest. Vials are labeled with a unique BSI ID 
which is printed in both eye-readable and bar-co ded format. No patient-specific information is 
encoded in this ID. 
Investigators are granted view, input, and withdraw authority only for their specimens. They may 
not view specimen data or access specimens for which they have not been authorized. Access to 
specimen storage is confined to repository staff. Visitors to the repositories are escorted by 
repository staff at all times.
Samples will be used for research analysis, including immunologic monitoring as outlined in
section 4.1.3. All specimens for analysis will be requested from Leidos Biomedical Research,
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
38Inc. and will be delivered by Leidos Biomedical Research, Inc. couriers to the Laboratory of 
Tumor Immunology and Biology.
4.2.1 Protocol Completion/ Sample Destruction
Once primary research objectives for the protocol are achieved, intramural researchers can 
request access to remaining samples, provided th ey have an IRB-approve d protocol and patient 
consent.Samples and associated data will be stored permanently unless the patient withdraws consent. If
the patient withdraws consent the participant’s data will be excluded from future distributions, but data that have already been distributed for approved research use will not be able to be retrieved. The PI will report destroyed samples to the IRB if samples become unsalvageable or destroyed by environmental conditions (ex. br oken freezer or lack of dry ice in shipping 
container) or if a patient chooses to withdraw his/her consent. Samples wi ll also be reported as 
lost if they are lost in transit or misplaced by a researcher. Freezer problems, lost samples or other problems associated with samples will also be reported to the IRB, the NCI Clinical 
Director, and the office of the CCR, NCI.
5 SUPPORTIVE CARE
For both the administration of PSA-TRICOM and enzalutamide, antiemetics, stool softeners and 
antidiarrheal agents may be administered as requi red, but are not anticipated to be needed and 
should not be used prophylactically on the first cycle. The selection of the specific antiemetic 
regimen is at the discretion of the treating physician. Antiemetic regimens will not include steroids.
Other supportive care with blood components, antib iotics, analgesics, general medical therapy, 
etc., will be delivered as required. Any patients taking antibiotics for any reason must complete 
that course of therapy and be free of evidence of  further infection before receiving any dose of 
vaccine.
Symptomatic anemia should be treated with appropriate red blood cell or erythropoietin support.
Thrombocytopenia should be treated conservativel y. In the absence of bleeding or a planned 
invasive procedure, platelet transfusions should be given for a platelet count below 10,000/mm
3.
If invasive procedures are planne d or the patient develops bleeding, platelet transfusions should 
be administered in accordance with the standard of  practice, usually maintaining a platelet count 
of > 50,000/mm 3.
Any evidence of disseminated intravascular coagulation (DIC), hemolytic uremic syndrome 
(HUS), or thrombotic thrombocytopenic purpura (TTP) including thrombocytopenia, hemolytic 
anemia, renal failure, fever or neurologic chan ges should be thoroughly evaluated and closely 
monitored and supported as  clinically indicated.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
395.1 E XCLUDED MEDICATIONS
While patients on protocol  treatment, all medicati ons required for the health of the patient are 
allowed with the following exceptions :
xConcurrent chemotherapy
xConcurrent radiation therapy
xConcurrent immunotherapy
xConcurrent anti-cancer radionuclides
xConcurrent systemic corticosteroid use (daily or every other day for continued use >
14 days ; See section 2.1.2)
xConcomitant use of secondary hormonal treatments
5.2 T REATMENT OF VACCINIA VACCINATION COMPLICATION
5.2.1 Vaccinia Immune Globulin:
First-line treatment of some of the complications of vaccinia caused by dissemination of vaccinia
virus (severe cases of inadvertent inoculati on involving extensive lesions or if comorbid
conditions exist, severe cases of generalized vaccinia in patients that are systemically ill andwhose condition might be toxic or who have serious underlying immunos uppressive illnesses,
eczema vaccinatum, and progressive vaccinia) is with VIG.
VIG is contraindicated, however, for the treatment of isolated vaccinial keratitis. VIG is a sterile
solution of the immunoglobulin fraction of pooled  plasma from individuals inoculated with
vaccinia vaccine. VIG is an investigational agent available through the CDC’s Strategic NationalPharmaceutical Stockpile under an IND protocol  by contacting the CDC’s Smallpox Vaccine
Adverse Events Clinician Information Line at 1-877-554-4625. Upon receipt of a call from apatient or upon direct observation of a patient or contact who ma nifests signs and symptoms of
any of the above conditions, the investigator s hould place a call to the CDC as soon as possible:
1) to initiate review of the clinical case, 2) to seek consultation on the appropriateness of VIG therapy, 3) to determine the appropriate VIG dose and dosing method for administration, if VIG
therapy is required, and 4) to determine how to access and have the appropriate doses of VIG delivered.
Early institution of VIG therapy is advised following recognition of clinical symptomscompatible with some vaccinia complications (eczema vaccinatum, severe generalized vaccinia,progressive vaccinia, and some cases of inadve rtent inoculation). The effectiveness of VIG
therapy appears to be time dependent. VIG has not  proven to be of bene fit in the treatment of
post-vaccinial encephalitis, and is contraindicated for treatment of  isolated vaccinial keratitis due
to the increased risk of corneal scarring.A new intravenous formulation of VIG is available through the CDC, which has a lower level ofaggregated protein, allowing it to be used by e ither the IM or IV route. This formulation will
most likely be preferred for administration and investigators will be instructed by the CDCregarding appropriate dosing and method of  administration based on formulation and
availability. There is no guarantee that VIG w ill successfully treat complications. At present,
there are no other anti-viral therapies of proven benefit for the treatment of vaccinia-relatedcomplications.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
405.2.2 Cidofovir (Vistide®, Gilead Sciences):
Cidofovir is an FDA-approved antiviral drug for the treatment of CMV retinitis among patients
with AIDS. Cell-based in vitro studies and animal model studies  have demonstrated antiviral
activity of this agent against certain orthopoxvi ruses. Currently, efficacy in the treatment of
vaccinia-related complications in humans is unknown. According to the CDC, “VIG isrecommended as first line of therapy. Cidofovir may be considered as a secondary treatment, and will only be released by the CDC after all inventories of VIG have been exhausted, after a patient fails to improve with VIG treatment, or as a last  effort for a patient who is otherwise near death.” 
[Medical Management of Smallpox (Vaccinia) Vaccine Adverse Reactions: VacciniaImmune Globulin and Cidofovir. Last updated February 11, 2003. Available at:
http://www.bt.cdc.gov/agent/smallpox/v accination/mgmt-a dv-reactions.asp ].
6 DATA COLLECTION AND EVALUATION
6.1 D ATA COLLECTION
The PI will be responsible for overseeing entry of data into an in-house password protected 
electronic system and ensuring data accuracy, consistency and timeliness. The principal 
investigator, associate investigators/research nurses and/or a contracted data manager will assist with the data management efforts.  All data obtained during the conduct of the protocol will be kept in secure network drives or in approved alternative sites that comply with NIH security 
standards. Primary and final analyzed data will have identifiers so that research data can beattributed to an individua l human subject participant.
6.1.1 Eligible patients must be confirmed and checklist completed. Consent form must be 
signed prior to registration with Central Registration Information Services.
6.1.2 Data will be secured in NCI C3D database. Da ta will be collected using protocol-specific 
case report forms, and verified for accuracy an d completeness. Hard c opies of data will 
be stored in locked secured areas and data will be entered onto a secured electronic data base. The following protocol-specific study forms will be complete and stored: eligibility checklist (developed by Central Registration Office, CRO). A copy of all serious AE 
forms will be kept in the research record.
6.1.3 Treatment is given according to protocol (dated notes about doses given, complications, 
and clinical outcomes).
6.1.4 Toxicity is assessed according to protocol (laboratory report slips, etc.)
6.1.5 Response is assessed accordin g to protocol (X-ray, scan, lab reports, and date noted on 
clinical assessment, as appropriate).
6.1.6 Drug Accountability Records are kept for each patient.6.1.7 We will not report Grade 1 adverse events.
All adverse events, including clinically significant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return to baseline or stabilization of event. Patients will be followed for adverse events for a minimum of 30 days after removal from study treatment or until off-study, whichever comes first.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
41An abnormal laboratory value will be re corded in the database as an AE only if the laboratory 
abnormality is characterized by any of the following:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other therapeutic intervention
xIs associated with death or another seri ous adverse event, including hospitalization. 
xIs judged by the Investigator to be of significant clinical impact
xIf any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patient’s outcome.
End of study procedures: Data will be stored according to HHS, FDA regulations and NIH 
Intramural Records Retenti on Schedule as applicable. 
Loss or destruction of data: Should we become aware that a majo r breach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified. 
6.2 R
ESPONSE CRITERIA
Patients will not undergo scheduled radiographic assessment for metastatic disease unless 
clinically indicated for increasing PSA or symptoms.
6.2.1 Disease Progression 
6.2.1.1 PSA will not be used to measure progressi on of disease given the intermittent use of 
enzalutamide.  It is expected that PSA will rise after a 3 month course of enzalutamide 
is completed and the treatment is discontinued.  Patients will be offered androgen deprivation therapy (ADT) as clinically indicated or a second course of enzalutamide as indicated in the protocol.  Starting ADT will be done at the discretion of the investigator, although this will result in treatment termination and removal from the 
clinical trial.  (Conventionally this is when PSA has a doubling time of less than 3 
months, but patients may refuse treatment in favor of surveillance which is also clinically appropriate.  Conversely, patie nts may go on ADT at any time, although this 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
42may result in removal from the trial.) PSA w ill be used to calculate PSA kinetics/tumor 
growth kinetics.
6.2.1.2 Development of a new bone lesion.
6.2.1.3 Development of a soft tissue mass, identifie d on CT scan or physical exam, consistent 
with metastatic prostate cancer. If identified on physical exam, the lesion may be 
biopsied to confirm the presence of prostate cancer.
6.2.1.4 Development of urethral, ureteral, or sp inal cord obstruction secondary to tumor.
6.2.1.5 Development of cytologically positive pleural effusion or lymphangitic spread in the 
lungs.
6.2.1.6 Symptoms which in the opinion of the investigator are consistent with clinical 
progression.
6.3 T OXICITY CRITERIA
The following adverse event management guidelines are intended to ensure the safety of each patient while on the study.  The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events  (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 ). 
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
7.1 D EFINITIONS
7.1.1 Adverse Event
Any untoward medical occurrence in a human  subject, including any abnormal sign (for 
example, abnormal physical exam or laboratory finding), symptom, or disease, temporally 
associated with the subject’s participation in re search, whether or not considered related to the 
subject’s participation in the research.7.1.2 Suspected adverse reactionSuspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.
7.1.3 Unexpected adverse reactionAn adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in 
the investigator brochure or is not listed at the sp ecificity or severity that has been observed; or, 
if an investigator brochure is not  required or available, is not cons istent with the risk information 
described in the general inve stigational plan or elsewhere in the current application. 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
43"Unexpected”, also refers to adverse events or suspected adverse reactions that are mentioned in 
the investigator brochure as occurring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are not specifically mentioned as occurring with the 
particular drug und er investigation.
7.1.4 Serious 
An Unanticipated Problem or Prot ocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety , welfare or rights of subjects or others.
7.1.5 Serious Adverse EventAn adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
xDeath,
xA life-threatening adverse drug experience
xInpatient hospitalization or prolongation of existing hospitalization
xPersistent or significant incapacity or s ubstantial disruption of  the ability to conduct 
normal life functions
xA congenital anomaly/birth defect.
xImportant medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious  adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a person’s  ability to conduct normal life functions.
7.1.7 Life-threatening adverse drug experience
Any adverse event or suspected adverse reaction that places the patient or subject, in the view of 
the investigator or sponsor, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that had it occurred in  a more severe form, might have caused death.
7.1.8 Protocol Deviation (NIH Definition)
Any change, divergence, or departure fro m the IRB-approved research protocol.  
7.1.9 Non-compliance (NIH Definition)The failure to comply with applicable NIH Human Research Protections Program (HRPP) 
policies, IRB requirements, or regulatory requirements for the protection of human research 
subjects.
7.1.10 Unanticipated ProblemAny incident, experience, or outcome that:
xIs unexpected in terms of nature, se verity, or frequency in relation to 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
44(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents, and
(b) the characteristics of the subject population being studied; AND
xIs related or possibly related to participation in the research; AND
xSuggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.
7.2 NCI-IRB AND CLINICAL DIRECTOR REPORTING
7.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths
The Protocol PI will report in the NIH Problem Form to the NCI-IRB and NCI Clinical Director:
xAll deaths, except deaths due to progressive disease 
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
Reports must be received within 7 days of PI awareness via iRIS.
7.2.2 NCI-IRB Requirements for PI Reporting at Continuing ReviewThe protocol PI will report to the NCI-IRB: 
1. A summary of all protocol deviations in a ta bular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibly, probably or definitely related to the 
research; 
xAll Grade 3 and 4 events that are possibly,  probably or definitely related to the 
research; 
xAll Grade 5 events regardless of attribution; 
xAll Serious Events regardless of attribution. 
NOTE : Grade 1 events are not required to be reported. 
7.2.3 NCI-IRB Reporting of IND Safety Reports
Only IND Safety Reports that meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
457.3 IND S PONSOR REPORTING CRITERIA 
During the first 30 days after the subject re ceives investigational agent/intervention, the
investigator must immediately report to the sponsor, using the mandatory MedWatch form 
3500a, any serious adverse event, whether or not c onsidered drug related, including those listed 
in the protocol or investigator  brochure and must include an a ssessment of whether there is a 
reasonable possibility that the drug caused the event. For serious adverse events that occur more 
than 30 days after the last administration of investigational agent/intervention, only report those 
that have an attribution of at least possibly related to the agent/intervention.
Required timing for reporting per the above guideline:
xDeaths (except death due to progressive dis ease) must be reported via email within 
24 hours.  A complete report must be  submitted within one business day. 
xOther serious adverse events as well as de aths due to progressive disease must be 
reported within one business day
Events will be submitted to the Center for Cancer Research (CCR) at: CCRsafety@mail.nih.gov,
and to the CCR PI and study coordinator.
7.3.1 Reporting Pregnancy 7.3.1.1 Paternal exposureMale patients should refrain from fathering a ch ild or donating sperm during the study and for 3 
months after the last dose of study treatment.  Pregnancy of the patie nt’s partner is not considered 
to be an AE. However, the outcome of all pregnancies (spontaneous miscarriage, elective 
termination, ectopic pregnancy, nor mal birth, or congenital abnorma lity) occurring from the date 
of the first dose until 3 months after the last  dose should, if possible, be followed up and 
documented.
7.4 S
AFETY REPORTING CRITERIA TO THE PHARMACEUTICAL COLLABORATORS 
All events listed below must be reported in the defined timelines to CCRsafety@mail.nih.gov .
The CCR Office of Regulatory Affairs will send all reports to the manufacturer as described 
below.
7.4.1 Reporting to Astellas
The Investigator should complete and submit an SAE Medwatch 3500 Form, containing all 
information that is required by the Regulatory Authorities, to Astellas by either e-mail or fax 
within 24 hours of awareness whether or not relate d to the study drug. If submission of this SAE 
by email or fax or is not possible within 24 hours, the local drug safety contact (IRB, 
Investigator, etc.) should be informed by phone.
The SAE documentation, including the Medwat ch 3500 Form and available source records, 
should be emailed or faxed to:
Astellas Pharma Global Development – United States
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
46Email: Safety-us@us.astellas.com
Fax number: (847) 317-1241
The following minimum information is required:
xStudy number/IIT regulatory identifier
xSubject number, sex and age
xThe date of report
xA description of the SAE (eve nt, seriousness of the event)
xCausal relationship to the study drug
Follow-up information for the event should be sent within 7 days as necessary.
7.4.2 Reporting to Bavarian Nordic, Inc.
The investigator should also submit all safety reports that are sent to the FDA using the 
Medwatch 3500 Form to:
Bavarian Nordic, Inc. 
Email: pharmacovigilance@bavarian-nordic.com ;
Fax number for pharmacovigilance at BN: 888-465-1219
Attention: Karen Latina
7.5 I NSTITUTIONAL BIOSAFETY COMMITTEE (IBC) R EPORTING CRITERIA
7.5.1 Serious Adverse Event Reports to OSP/IBC
The Principal Investigator (or delegate) will notify IBC of any unexpected fatal or life-
threatening experience associated with the us e of PSA-TRICOM Vaccine as soon as possible but 
in no event later than 7 calendar days of initial receipt of the information.  Serious adverse events that are unexpected and associated with the use of the PSA-TRICOM Vaccine, but are not fatal or life-threatening, much be reported to the NIH IBC as soon as possible, but not later than 15 
calendar days after the investigator’s initial receipt of the information.  Adverse events may be reported by using the FDA Form 3500a.
7.5.2 Annual Reports to IBCWithin 60 days after the one-year anniversary of the date on which the IBC approved the initial 
protocol, and after each subsequent anniversary until the trial is completed, the Principal Investigator (or delegate) shall submit the information described below.  Alternatively, the IRB continuing review report can be sent to the IBC in  lieu of a separate repor t.  Please include the 
IBC protocol number on the report.
7.5.2.1 Clinical Trial Information 
A brief summary of the status of the trial in progress or completed during the previous year. The 
summary is required to include the following information: 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
47xthe title and purpose of the trial 
xclinical site
xthe Principal Investigator
xclinical protocol identifiers; 
xparticipant population (such as disease indication and general age group, e.g., adult or 
pediatric); 
xthe total number of participants planned for inclusion in the trial; the number entered into 
the trial to date whose participation in the trial was completed; and the number who dropped out of the trial with a bri ef description of the reasons 
xthe status of the trial, e.g., open to accrual of subjects, closed but data collection ongoing, 
or fully completed, 
xif the trial has been completed, a brief description of any study results. 
7.5.2.2 Progress Report and Data Analysis
Information obtained during the previous year's  clinical and non-clin ical investigations, 
including: 
xa narrative or tabular summary showing th e most frequent and most serious adverse 
experiences by body system
xa summary of all serious adverse events submitted during the past year
xa summary of serious adverse events that were expected or considered to have causes not 
associated with the use of the gene transf er product such as disease progression or 
concurrent medications
xif any deaths have occurred, the number of pa rticipants who died during participation in 
the investigation and causes of death
xa brief description of any information obtained that is pertinent to an understanding of the 
gene transfer product’s actions, including, fo r example, informati on about dose-response, 
information from controlled trials, a nd information about bioavailability. 
7.6 D
ATA AND SAFETY MONITORING PLAN
7.6.1 Principal Investigator/Research Team 
The Principal Investigator, lead associate investigator and the research nurse will meet weekly at 
each clinic to review all adverse events for each subject in this trial and to determine dose limiting toxicities and escalation rules.  Unexpected adverse events and/or serious adverse events will be reported to the NCI’s Institutional Review Board (IRB ) and sponsor/FDA as outlined 
above.  If trends are noted and/or risks warr ant it, accrual will be in terrupted, dose levels 
expanded and/or the protocol and/or consent will be modified accordingly.
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. Adverse events will be reported as required above. Any safety concerns, 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
48new information that might affect  either the ethical and or scie ntific conduct of the trial, or 
protocol deviations w ill be immediately reported to the IRB using iRIS and to the Sponsor. 
The principal investigator will review adverse ev ent and response data on each patient to ensure 
safety and data accuracy. The principal invest igator will personally conduct or supervise the 
investigation and provide appr opriate delegation of responsib ilities to other members of the 
research staff. 
7.6.2 Sponsor Monitoring Plan
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring 
program. The CCR’s program allows for confirmation of: study data, specifically data that could affect the interpretation of primary study endpoints; adherence to  the protocol, regulations, and 
SOPs; and human subjects protection. This is done  through independent verification of study 
data with source documentation focusing on:
xInformed consent process
xEligibility confirmation
xDrug administration and accountability
xAdverse events monitoring
xResponse assessment.
The monitoring program also extends to multi-site research when the CCR is the coordinating center.This trial will be monitored by personnel employed  by an NCI contractor. Monitors are qualified 
by training and experience to monitor the progres s of clinical trials. Personnel monitoring this 
study will not be affiliated in any way with the trial conduct. Safety Monitoring Committee 
(SMC)
This protocol will require oversight from the Safety Monitoring Committee (SMC).  Initial 
review will occur as soon as possible after the annual NCI-IRB continuing review date.   Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting 
schedule permits or more frequently as may be required by the SMC.   For initial and subsequent reviews, protocols will not be reviewed if th ere is no accrual within the review period. Written 
outcome letters will be generated in response to the monito ring activities and submitted to the 
Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.
8 STATISTICAL CONSIDERATIONS
8.1.1 Cohort 1The primary objective of this study is to compare th e change in the growth rate in the two arms 
from the time of discontinuation of enzalutamide (3 months after enrollment) to 4 months after 
completing enzalutamide therapy +/- PSA-TRICOM (7 months after enrollment). With growth 
rate changes obtained on all patie nts on both arms, and if the grow th rate changes in the two 
arms had the same standard de viation, with 17 patients per arm,  there would be 80% power to 
detect a difference between the arms equal to 1 SD of the difference from baseline to 7 months 
with a two-tailed 0.05 signifi cance level two-group t-test .Thus, a total of 34 evaluable patients 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
49are required for analysis. To allow for a sma ll number of patients w ho do not develop a 25% 
decline in PSA after 3 months, additional patients will be randomized if necessary to obtain a 
minimum of 17 evaluable patients on each arm. In  order to allow for a small number of such 
patients, the accrual ceiling will be 38.
Patients will be stratif ied based a doubling time of greater than or less than 6 months.  
Secondary endpoints will be compared between th e two arms using appr opriate non-parametric 
tests, such as a Wilcoxon rank sum test.  Results  will be presented without formal adjustment for 
multiple comparisons but reported in the context of secondary evaluation of a potentially large 
number of endpoints. The significance of paired  hormone level results within arms will be 
determined by a paired t-test or W ilcoxon signed rank test as appropriate.
8.1.2 Halting Rules
The study will be halted for review of changes to the protocol and consent if either of the
following is met:
xOne occurrence of grade 5 toxicity attributed to the treatment regimen.
xTwo occurrences of grade 4 toxicity attributed to the treatment regimen.
8.1.3 The regression-growth equation
The equation is f(t) = exp(-d * t)+exp(g * t) - 1 (A) where exp is the base of the natural 
logarithm, e= 2.7182, and f(t) is the tumor (or in MTC calcitonin) measurement at time tin days, 
normalized to (divided by) the tumor measurement at day 0, the time at which treatment is 
commenced. Rate constant d(decay, in daysí) represents the exponential decrease/regression of 
the a serum tumor marker (i.e. PSA) signal during therapy. Rate constant g(growth, also in 
daysí) represents the exponential growth/regrowth of the tumor during treatment. These rate 
constants may be expressed in terms of half-lives and doubling times. Thus, dequals ln 2(0.693) 
divided by the time it takes for the regressing part to shrink by half, whereas gequals ln 2divided 
by the time for the growing component to double. ( 44)
Two earlier papers depict theoretical curves de picting the separate components of Equation (A) 
and how these combine together to give the time dependence of the tumor size,  f.(44)When the 
data showed a continuous decrease from the time of treatment start, so that only the regression 
parameter dwas found to differ significantly from zero with P< 0.05, Equation (A) was replaced 
by the following reduced form, with the growth rate constant eliminated: f(t) = exp(-d * t )( B )
When tumor measurements showed a continuous increase, so that only the growth parameter g
was found to differ significantly from zero with P< 0.05, Equation (A) was replaced by the 
following reduced form, with the decay constant eliminated: f(t) = exp(g *t) .
8.1.4 Data Analysis 
For each patient an attempt to fit Equation (A) to each data set for which more than one data 
point is available. Curve fittingbo will be performed using Sigmaplot (Systat Software), or by 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
50using the Solver routine in an Excel spreadsheet. We will extract parameters g and d with their 
associated Student's t and P values. ( 44) Data will be analyzed in Excel (Microsoft) and in 
Sigmaplot 9.0. Linear regressions to evaluate the relationship between the growth rate constant,
g, or other parameters will be implemented using the polynomial linear routine of Sigmaplot 9.0. 
Sample comparisons were performed by Student's t-test, using SigmaStat 3.5 (Systat Software), 
with Pset at 0.05 for significance. ( 44)
9 COLLABORATIVE AGREEMENTS 
9.1 A GREEMENT TYPE
9.1.1 Cooperative Research and Development Agreement (CRADA)
xA CRADA (#02859) is in place with Me divation and Aste llas to provide 
enzalutamide.
xA CRADA (#02377) is in place with Bava rian Nordic to provide PSA-TRICOM.
9.1.2 Material Transfer Agreement (MTA) 
xA MTA is in place with The Cleveland Clin ic Foundation for the studies discussed in 
section 4.1.6 (MTA#4122006).
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
5110 HUMAN SUBJECT PROTECTIONS 
10.1 RATIONALE FOR SUBJECT SELECTION
10.1.1 Selection Based on Gender, Ethnicity, and Race 
Subjects from all racial/ethnic groups are eligible for this study if they meet the eligibility criteria. 
To date, there is no information that suggests th at differences in drug metabolism or disease 
response would be expected in one group compared with another. Efforts will be made to extend 
accrual to a representative population, but in this  preliminary study, a balance must be struck 
between patient safety considerations and limitations on the number of individuals exposed to potentially toxic and/or ineffective treatments on one hand and the need to explore ethnic aspects 
of clinical research on the other hand. If differences in outcome that correlate with ethnic identity are noted, accrual may be expanded or a follow- up study may be written to investigate those 
differences more fully. Women are not eligible for this study as this diease occurs only in men.
10.1.2 Strategies/Procedures for RecruitmentPatient accrual for this protocol will be facilitated by Web-based recruitment strategies. This 
protocol will be listed on www.clinicaltrials.gov .
10.1.3 Justification for ExclusionsDue to impaired cellular immunity with the concomitant increased risk of serious side effects from 
vaccinations with infectious agents, the Centers for Disease Control and Prevention recommends that HIV infected patients be excluded, in addition, patients with chronic hepatitis infection, including B 
and C, because of potential immune impairment.
10.2 P
ARTICIPATION OF CHILDREN
Men under the age of 18 will not be eligible for par ticipation in this study based on the fact that 
patients under 18 are unlikely to have this diseas e and there are unknown toxicities in pediatric 
patients.10.3 P
ARTICIPATION OF NIH S UBJECTS UNABLE TO GIVE CONSENT
Adults unable to give consent are excluded from enrolling in the protocol.  However re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become decisionally impaired. For this reason and because there is a prospect of direct benefit from research participation (section 7.5), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance Directive for Health Care and Medical Research Participation” form so that another person can 
make decisions about their medical care in th e event that they become incapacitated or 
cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team for evaluation.  For those subjects that become incapacitated and do not have pre-determined substitute decision maker, the procedures described in MEC Policy 87-4 for appointing a su rrogate decision maker for adult subjects who 
are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
5210.4 E VALUATION OF BENEFITS /RISKS/DISCOMFORTS
There is no standard therapy for patients with prostate cancer and rising PSA following local 
definitive therapy. Potential risks of vaccine a nd enzalutamide therapy in  this patient population 
include the range of side effects outlined in section 9. Both drugs have been  well tolerated in 
previous large trials and there are no anticipated overlapping toxicities for patients getting both 
drugs.
10.4.1 Alternative Approaches or Treatments
Patients will be advised verbally and in writing regarding the risks and benefits of this trial, 
treatment requirements, and alternative approaches to entering the trial. Written consents will be obtained.
10.4.2 Procedures to Eliminate or  Minimize Potential Risks
This study may involve unforeseeable risks for pati ents, such as side eff ects whose exact nature 
and severity are unpredictable. Scrupulous care wi ll be taken to minimize such side effects. All 
patients will be given blood tests, physical examinations, and scans, as described in the 
monitoring schedule ( Appendix C ), and must have a local physician to provide long-term care 
and monitoring for complications. Immediate medical treatment is available at the Clinical Center, NCI, Bethesda, Maryland, for any patient s who suffer physical injury as a result of 
participation in this study. No compensation is available, but any injury will be evaluated and 
treated in keeping with the benefits or car e to which patients are entitled under applicable 
regulations.
10.4.3 Provisions for Monitoring Data Collection to Ensure Subject Safety As information is gathered from this trial, clinical results will be shared with patients.  
Laboratory and clinical data w ill be frequently gathered and an y new significant finding(s) found 
during the course of the research, which may affect a patient’s willingness to participate further, will be explained.
Confidentiality of information concerning participants will be maintained, including in all 
publications and presentations resulting from this study.  Names of participants or material identifying participants will not be released without permission, except as such release is 
required by law.  Records at the National Cancer Institute are maintained according to current legal requirements, and are ma de available for review, as required by the Food and Drug 
Administration or other authorized users, only und er the guidelines established by the Federal 
Privacy Act.
10.5 R
ISKS/BENEFITS ANALYSIS
This study involves clinical research with an experimental vaccine designed to generate an 
immune response against antigens found in pros tate cancer. Patients will undergo multiple 
vaccinations. Side effects of the vaccin e are outlined elsewhere (see section 11).  Whether the 
vaccine will have any clinical effect is unknown; therefore, benefit cannot  be promised, nor the 
chance of benefit accurately predicted.  Enzalu tamide is an FDA-approved therapy with a known 
and minimal toxicity profile (section 11). Participation in this study is voluntary, and refusal will 
not result in penalty or loss of benefit to which the patient is otherwise entitled.   
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
53The standard of care for patients with nm CSPC includes ADT and active surveillance.  
Generally, these patients can be followed without  therapy until their PSA doubling time escalates 
at which time ADT is often starte d.  All patients in the proposed tr ial will receive enzalutamide.  
Based on previous trials with high dose bical utamide, 34 of 36 evaluable patients had PSA 
declines by a median of 96.5% and these nadi rs were achieved within the first 4 weeks of 
treatment ( 10). We would expect similar if not better results with enzalutamide.  Therefore, a
clinical trial in this population is  ethical and appropriate.  The NC I has conducted several trials in 
this population previously.  
Participation may be discontinued at any time  without penalty, a nd the patient will be 
encouraged to discuss any concerns or questions.
10.6 C ONSENT AND ASSENT PROCESS AND DOCUMENTATION
The investigational nature and objectives of this trial, the procedures involved, and their 
attendant risks and discomforts, potential benefits, and potential alternative therapies will be 
explained to the patient and a signed informed  consent obtained. Any experimental invasive 
procedure will require a separate consent form. All Associate Investigators listed in this protocol who have clinical privileges are permitted to obtain informed consent. For the apheresis for research in the protocol, the patient will consent at the time of the procedures.  If the patient refuses the apheresis at that time, the refusal will be documented in the medical record and in the research record.
10.6.1 Telephone Re-Consent Procedure
Re-consent on this study may be obtained via te lephone according to the following procedure: 
the informed consent document will be sent to the subject. An explanation of the study will be 
provided over the telephone after the subject has had the opportunity to read the consent form. 
The subject will sign and date the informed consent. A witness to the subject’s signature will sign and date the consent.  The original informed consent document will be sent back to the consenting investigator who will sign and date the consent form with the date the consent was obtained via telephone. A fully executed copy will be returned via mail for the subject’s records.  
The informed consent process will be documented on a progress note by the consenting investigator and a copy of the informed consent document and note will be kept in the subject’s research record.
10.6.2 Informed Consent of Non-English Speaking Subjects
If there is an unexpected enrollment of a research participant for whom there is no translated 
extant IRB approved consent document, the princi pal investigator and/or those authorized to 
obtain informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77-2, OSHRP SOP 12, 45 CFR 46.117 (b) (2), and 21 CFR 50.27 (b) (2).  The summary that will be used is the English version of the extant IRB approved consent document.  Signed copies of both the English version of the consent and the translated short form will be 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
54given to the subject or their legally authorized representative and the signed original will be filed 
in the medical record.
Unless the PI is fluent in the prospective subject’s language, an interpreter will be present to 
facilitate the conversation (using either the long translated form or the short form). Preferably someone who is independent of th e subject (i.e., not a family member) will assist in presenting 
information and obtaining consent. Whenever possible, interpreters will be provided copies of the relevant consent documents well before the consent conversa tion with the subject (24 to 48 
hours if possible). 
We request prospective IRB approval of the use of the short form process for non-English 
speaking subjects and will notify the IRB at the time of continuing review of the frequency of the 
use of the Short Form.
11 PHARMACEUTICAL AND INVESTIGATIONAL DEVICE INFORMATION
11.1 RECOMBINANT FOWLPOX -PSA(L155)/TRICOM 
Other Names: PROSTVAC-F/TRICOM ; PROSTVAC-F
Classification: Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus.
Product Description: Recombinant Fowlpox-PSA(L155)/TRICOM is a recombinant 
fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory 
molecules (designated TRICOM ): B7.1, ICAM-1 (intercellula r adhesion molecule-1), and 
LFA-3 (leukocyte function-associated antigen-3). The PSA gene coding sequence is modified to 
code for a single amino acid substitution [isoleucine to leucine at amino acid position 155 of the 
PSA antigen (designated L155)], which is designed to enhance immunogenicity. This modification 
occurs in a 10-mer, HLA-A2-restricted, immunodominant epitope of the antigen [designated PSA-3 (amino acids 154-163)]. An attenuated, live, plaque-purified isolate from the POXVAC-TC 
strain of fowlpox virus was used as the parental virus for this recombinant vaccine. A plasmid vector containing the modified PSA gene and the genes for the three co-stimulatory molecules is used for in vivo recombination between the plasmid vector  and parental fowlpox virus genome. 
The recombinant vaccine is manufactured by infection of primary chicken embryo dermal (CED) cells with the recombinant fowlpox virus. Fowlpox virus can infect mammalian cells and express the inserted transgenes to stimulate both humo ral and cellular immunity, but cannot replicate in 
non-avian species, making systemic infections unlikely. 
11.1.1 How Supplied 
Recombinant Fowlpox-PSA(L155)/TRICOM is supplied in vials containing 0.75 mL of the 
vaccine at a final viral concentration titer of 2 x 109infectious units/mL formulated in phosphate-
buffered saline containing 10% glycerol.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
5511.1.2 Preparation 
Thaw vials completely at room temperature. Ensure the thawed contents are at the bottom of the 
upright vial and vortex vigorously at high power for at least ten seconds prior to dose preparation. 
Withdraw 0.5 mL (1 x 109infectious units) into a 1 mL syring e for administration by subcutaneous 
injection.
11.1.3 Storage 
Store intact vials of Recombinant Fowlpox-PSA(L155)/TRICOM at –70oC or colder. 
11.1.4 Stability
Shelf-life stability studies of the intact vials are ongoing. Once the intact vials are thawed, the vaccines 
maintain their potency for up to 4 days when stored at 2-8oC. Do not re-freeze thawed vials. Vials of 
Recombinant Fowlpox-PSA(L155)/TRICOM are for single-use only and do not contain a 
preservative. Administer prepared doses as  soon as possible following preparation ( i.e., within one 
hour). If necessary, store prepared doses at 2-8oC for up to 4 hours following preparation.
11.1.5 Route of Administration 
Recombinant Fowlpox-PSA(L155)/TRICOM is administered by subcutaneous injection. 
11.1.6 Special Handling
Fowlpox virus is classified as a Biosafety Level 1 agent.  These agents are not known to cause 
disease in healthy human adults and are of  minimal potential hazard  to personnel and the 
environment under ordinary conditi ons of use. Clinicians can use techniques generally acceptable 
for nonpathogenic material. The recombinant vaccine is a preparation of a live virus (infectious 
for birds) containing DNA se quences derived from the human genome. Handle the recombinant 
vaccine as a hazardous biological substance and di spose of waste materials as hazardous biological 
waste, with incineration according to local institutional policy and according to local, state, and federal regulations. Healthcare workers handling the recombinant fowlpox vaccine should avoid 
direct contact with pet birds for at le ast 72 hours after working with the agent. 
Preparation, Handling and Disposal Recommendations 
1. Strictly adhere to standard microbiological practices and techniques.
2. Limit/restrict access to preparation areas while dose preparation is in progress. 3. Use appropriate infection control measures (e .g., thorough hand washing) after handling any 
materials.
4. Institute and follow policies for safe handling of sharps.5. Perform all dose preparations in a certified Class II biological safety cabinet, generally using 
procedures, guidelines and personal protective apparel used during preparation of antineoplastic agents [ e.g., minimizing creation of aerosols; no eating, drinking, handling 
contact lenses or applying cosmetics in the work area; using appropr iate personal protective 
apparel - gowns, sterile latex gloves (double-gloving is reco mmended), respirator masks, 
protective eye wear, hair cover]. 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
566. Decontaminate the biological sa fety cabinet prior to dose prepar ation with sterile gauze soaked 
in 10% bleach solution (0.52% sodium hypochlorite  solution), or other appropriate disinfectant 
suitable for decontamination, rinsing, then wi ping down with sterile gauze soaked in 70%
alcohol. Consult specific manufacturer’s reco mmendations with respect to disinfectant 
concentration, contact time and method of application. 
7. Have all necessary supplies on- hand before beginning the preparation procedure. Develop a 
detailed worksheet outlining all supplies, dose calculations, and preparation procedures, and 
keep it available.
8. Place an empty biohazard sharps container lined with a leak-proof biohazard bag in or near the 
biosafety cabinet to dispose of all waste generated.
9. Transport the agent from the freezer to the work area in leak proof bag. 10. Wipe or spray items used for dose prepara tion with 70% alcohol before placing in the 
biological safety cabinet. Disi nfectants should remain in contact with the surfaces for at least 
five minutes prior to dose preparation. Avoid exposing the virus to disinfectants.
11. Wipe the syringe containing the prepared dos e with 70% alcohol before removing it from the 
biological safety cabinet; transport it in a leak proof bag or container labeled with a biohazard 
symbol.
12. Place all waste into the sharps container lined with the leak proof biohazard bag and 
decontaminate the biological safety cabinet again by wiping down all surfaces with sterile gauze soaked in 10% bleach solution, or other a ppropriate disinfectant, rinsing, then wiping 
down with sterile gauze soaked in 70% alcohol. Following decontamination, dispose of personal protective apparel in  the biohazard safety bag.
13. Incinerate waste according to institutional policy and according to local, state, and federal 
regulations.
14. Handle accidental spills similarly to antineoplastic spills and/or according to institutional 
policy:
xPrevent others from entering the area and allow aerosols time to settle (approximately 10 minutes). 
xUse protective apparel, eyewear, mask, and gloves. 
xCover spills with disposable absorbent towels. 
xDecontaminate the area with 10% bleach solutio n, or other appropriate  disinfectant suitable 
for decontamination, allowing appr oximately a 20-minute contact time. 
xDispose of all waste as biohaza rdous waste and incinerate according to institutional policy 
and according to local, state, and federal regulations. 
15. Immediately report spills and accidents resu lting in overt exposure to recombinant DNA 
molecules to the Institutional Biosafety Committee and NIH/OSP (Office of Science Policy). Send reports to the Office of Science Policy,  National Institutes of  Health, 6705 Rockledge 
Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985. Phone (301) 496-9838. Provide 
medical evaluation, surveillance, and treatment as  appropriate and mainta in written records of 
the event.
For more information about biohazard risk  group classification and biohazard safety 
levels see:
xNIH Guidelines for Research Involving Recombinant DNA Molecules (NIH 
Guidelines). See current version at:
http://osp.od.nih.gov/sites/def ault/files/NIH_Guidelines.html
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
57xBiosafety in Microbiological and Biomedic al Laboratories; U. S. Department of 
Health and Human Services Centers for Disease Control and Prevention and 
National Institutes of Health. See current edition at:
http://www.cdc.gov/biosafety/publications/index.htm
Patient Care Implications and Contraindications 
Cover vaccination sites with a st erile dry dressing (e.g., Telfa pa d). Once the injection site is 
healed, no further barrier is necessary. As a precaution, protect injection sites that are 
exhibiting evidence of weeping, oozing or ulceration with a sterile dry dressing. In these 
circumstances, instruct patients to avoid direct contact of the injection site with susceptible individuals (e.g.; those who may be immunocom promised by disease or therapy). Instruct
patients to avoid fathering a child for at least 4 months following therapy completion with the recombinant vaccine. Instruct patients receiving fowlpox vaccines to avoid direct contact with pet birds for at least 72 hours after vaccination or while there are any visible lesions at the 
injection site.
Due to the method of manufacturing (virus  grown in primary chicken embryo dermal 
cells), patients with a history of allergy to eggs or egg products should not receive the 
vaccine.
11.2 R
ECOMBINANT VACCINIA -PSA(L155)/TRICOM 
Other Names: PROSTVAC-V/TRICOM ; PROSTVAC-V
Classification: Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus.
Product Description: Recombinant Vaccinia-PSA(L155)/TRICOM is a recombinant vaccinia 
virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules
(designated TRICOM ): B7.1, ICAM-1 (intercellular ad hesion molecule-1), and LFA-3
(leukocyte function-associated antigen-3). The PSA gene coding sequence is modified to code for 
a single amino acid substitution [isoleucine to leucine at amino acid position 155 of the PSA antigen 
(designated L155)], which is designed to enhance immunogenicity. This modification occurs in a 
10-mer, HLA-A2-restricted, immunodominant epitope of the antigen [designated PSA-3 (amino acids 154-163)]. An attenuated, live, derivative of the Wyeth (New York City Board of Health) strain of vaccinia virus is used as the parental virus for the recombinant vaccine. A plasmid vector containing the modified PSA gene and the genes for the three co-stimulatory molecules is used for in vivo recombination between the plasmid vector and parental vaccinia virus genome. The 
recombinant vaccine is manufactured by infection of primary chicken embryo dermal (CED) cells with the recombinant vaccinia virus. Vaccinia virus can infect mammalian cells and express the inserted transgenes, and is a potent immune stimulator, eliciting both a strong humoral and cellular immune response. Vaccinia virus is replication co mpetent in mammalian cells, making systemic 
infections possible.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
5811.2.1 How Supplied 
Recombinant Vaccinia-PSA(L155)/TRICOM is supplied in vials containing 0.75 mL of the 
vaccine at a final viral concentration titer of 4 x 108infectious units/mL formulated in phosphate-
buffered saline containing 10% glycerol. 
11.2.2 Preparation 
Thaw vials completely at room temperature. Ensure the thawed contents are at the bottom of the 
upright vial and vortex vigorously at high power for at least ten seconds prior to dose preparation. 
Withdraw 0.5 mL (2 x 108infectious units) into a 1 mL syring e for administration by subcutaneous 
injection.
11.2.3 Storage 
Store intact vials of Recombinant Vaccinia-PSA(L155)/TRICOM at –70oC or colder.
11.2.4 Stability
Shelf-life studies of the intact vials are ongoing. Once the intact vials are thawed, the vaccines 
maintain their potency for up to 4 days when stored at 2-8oC. Do not re-freeze thawed vials. Vials of 
Recombinant Vaccinia-PSA(L155)/TRICOM are for single-use only and do not contain a 
preservative. Administer prepared doses as  soon as possible following preparation ( i.e., within one 
hour). If necessary, store prepared doses at 2-8oC for up to 4 hours following preparation.
11.2.5 Route of Administration 
Recombinant Vaccinia-PSA(L155)/TRICOM is administered by subcutaneous injection. 
11.2.6 Special Handling and Precautions
Vaccinia virus is classified as a Biosafety Level 2 agent. These agents are associated with human 
disease and are of moderate potential hazard to  personnel and the environment. The recombinant 
vaccine is a preparation of a live virus affe cting humans and contains DNA sequences derived 
from the human genome. Handle the recombinant vacc ine as an infectious hazardous biological 
substance and dispose of waste materials as in fectious hazardous biological waste, with 
incineration according to local institutional policies and according to local, state, and federal 
regulations. 
Preparation, Handling and Disposal Recommendations 1. Prepare a biosafety manual which advises personnel of special hazards and specific 
instructions on practices and procedures.
2. Post warning hazard signs on access doors, identify ing the agents, the biosafety level, the name 
and phone number of the Principal Investigator or other responsible person, and any special 
requirements for entry.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
593. Establish policies and procedures allowing only personnel who are knowledgeable of the 
potential hazards and meet specific entry requirements ( e.g., immunization) into agent 
preparation or storage areas.
4. Strictly adhere to standard microbiological practices and techniques.
5. Limit/restrict access to preparation areas while dose preparation is in progress.6. Use appropriate infec tion control measures ( e.g., thorough hand washing) after handling any 
materials.
7. Institute and follow policies for safe handling of sharps. Use only needle-lock syringes and 
needles for dose preparation. Use extreme cauti on to prevent autoinoculation. Do not bend, 
shear, or replace the needle guard from the syringe following use. Promptly place used needles and syringes in puncture-resista nt containers for disposal.
8. Perform all dose preparations in a certified Class II biological safety cabinet, generally using 
procedures, guidelines and personal protective apparel used during preparation of antineoplastic agents [ e.g., minimizing creation of aerosols; no eating, drinking, handling 
contact lenses or applying cosmetics in the work area; using appropr iate personal protective 
apparel - gowns, sterile latex gloves (double-gloving is reco mmended), respirator masks, 
protective eyewear, hair cover]. 
9. Perform all procedures carefully to minimize aerosol creation.10. Decontaminate the biological safety cabinet pr ior to dose preparation with sterile gauze soaked 
in 10% bleach solution (0.52% sodium hypochlorite  solution), or other appropriate disinfectant 
suitable for decontamination, rinsing, then wi ping down with sterile gauze soaked in 70% 
alcohol. Consult specific manufacturer’s reco mmendations with respect to disinfectant 
concentration, contact time and method of application. 
11. Have all necessary supplies on-hand before be ginning the preparation procedure. Develop a 
detailed worksheet outlining all supplies, dose calculations, and preparation procedures, and keep it available.
12. Place an empty biohazard sharps container in the biosafety cabinet to dispose of all waste 
generated.
13. Transport the agent from the freezer to the work area in leak proof bag. 14. Wipe or spray items used for dose prepara tion with 70% alcohol before placing in the 
biological safety cabinet. Disi nfectants should remain in contact with the surfaces for at least 
five minutes prior to dose preparation. Avoid exposing the virus to disinfectants.
15. Wipe the syringe containing the prepared dose with 70% alcohol before removing it from the 
biological safety cabinet; transport it in a leak proof bag or container labeled with a biohazard 
symbol.
16. Place all waste into a sharps container lined with the leak proof biohazard bag and 
decontaminate the biological safety cabinet ag ain by wiping down all surfaces with sterile 
gauze soaked in 10% bleach solution, or other a ppropriate disinfectant, rinsing, then wiping 
down with sterile gauze soaked in 70% alcohol. Following decontamination, dispose of personal protective apparel in  the biohazard safety bag.
17. Place all waste and protective apparel in a leak proof biohazard bag, and place the bag inside 
a biohazard sharps container fo r incineration according to institutional policy and according to 
local, state, and federal regulations.
18. Handle accidental spills similarly to antineoplastic spills and/or according to institutional 
policy:
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
60a. Prevent others from entering the area and allow aerosols time to settle (approximately 10 
minutes). 
b. Use protective apparel, eyewear, mask, and gloves. 
c. Cover spills with disposable absorbent towels. d. Decontaminate the area with 10% bleach solutio n, or other appropriate  disinfectant suitable 
for decontamination, allowing appr oximately a 20-minute contact time. 
e. Dispose of all waste and protective apparel as  infectious biohazardous waste and incinerate 
according to institutional policy and according to local, state, and federal regulations. 
19. Immediately report spills and accidents resu lting in overt exposure to recombinant DNA 
molecules to the Institutional Biosafety Committee and NIH/OSP (Office of Science Policy). Send reports to the Office of Science Policy,  National Institutes of  Health, 6705 Rockledge 
Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985. Phone (301) 496-9838. Provide 
medical evaluation, surveillance, and treatment as appropriate an d maintain written records of 
the event.
For more information about biohazard risk gr oup classification and biohazard safety levels: 
xNIH Guidelines for Research Involving Recombinant DNA Molecules (NIH 
Guidelines). See current version at: http://osp.od.nih.gov/sites/def ault/files/NIH_Guidelines.html
xBiosafety in Microbiological and Biomedical  Laboratories; U. S. Department of 
Health and Human Services Centers for Disease Control and Prevention and 
National Institutes of Health. See current edition at: http://www.cdc.gov/biosafety/publications/index.htm
Precautions for Healthcare Workers
Recombinant vaccinia virus transmission risk to exposed healthcare workers is unknown. To date, 
no reports of transmission to healthcare personnel from vaccine recipients have been published. If 
appropriate infection control precautions are obser ved (such as covering the vaccination site and 
washing hands after contact with the vaccinat ion site or bandages), healthcare workers are 
probably at less risk of infecti on than laboratory workers because of the smaller volume and lower 
titers of virus in clinical specimens as compared with laboratory material. However, because of 
the potential risk for transmission, healthcare personnel who prepare or administer doses of 
recombinant vaccinia vaccine or have direct contact with contaminated dressings or other infectious material from participants in clinical studies must adhere to appropriate infection control measures and should be offered vaccination with the licensed vaccinia vaccine. Do not administer 
routine, non-emergency vaccination with the licensed  vaccinia vaccine to healthcare workers, if 
they, or for at least three weeks after vaccina tion, their close household contacts (close household 
contacts are those who share housing or  have close physical contact): 
xhave active eczema or a history of eczema or atopic dermatitis, or Darier’s disease.
xhave other acute, chronic, or exfoliative skin conditions (e.g., burns, imp etigo, varicella zoster, 
severe acne, or other open rashes or wounds), until the condition resolves.
xare pregnant or intend to become  pregnant within 4 weeks of vaccination or are breast-feeding.
xare immunodeficient or immunocompromised (b y disease or therapy), including HIV 
infection.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
61Additionally, do not administer routine, non-emer gency vaccination with the licensed vaccinia 
vaccine to healthcare workers if the vaccinee:  
xhas a moderate or severe acute illness, until the illness resolves.
xis less than 18 years of age, unless specifically indicated.
xis undergoing topical steroid therapy for inflamma tory eye diseases or undergoing therapy with 
systemic steroids; potential immune suppression increases ri sk for vaccinia-related 
complications. 
xhas a history of allergy or serious reaction to pr ior vaccinia vaccination or any of the vaccine’s 
components.
xAs a precaution, the CDC recommends that indi viduals with known cardiac disease (e.g., 
previous MI, angina, CHF, cardiomyopathy, stroke or TIA) or who have > 3 known risk factors 
for cardiac disease (e.g., hypertension, hyperc holesterolemia, diabetes, first degree relative 
with onset of cardiac complications prior to age 50, smoker), not receive routine, non-
emergency, prophylactic vaccination with the licensed vaccinia vaccine while a possible causal relationship between vaccination and cardiac events is being evaluated.
Avoid exposure to the recombinant vaccinia vaccine, any contaminated dressings, or other infectious materials from patients,  or the patient’s inoculation site  if you are pregnant or breast-
feeding; have a history or presence of active eczema or atopic dermatitis; have acute, chronic or exfoliative skin conditions; or, are immunocom promised. More information on vaccinia 
precautions for healthcare workers can be obtained from http://www.cdc.gov/mmwr/pre view/mmwrhtml/rr5010a1.htm#tab2 and 
http://www.cdc.gov/mmwr/PDF/rr/rr5207.pdf .
The CDC is the only source of the licensed vaccinia vaccine. The CDC will provide vaccinia vaccine to protect laboratory and other healthcare  personnel, whose occupati ons place them at risk 
of exposure to vaccinia and other closely re lated orthopoxviruses, including vaccinia 
recombinants. The vaccine should be administered under the supervision of a physician selected 
by the study institution. Revaccination is reco mmended every 10 years. For instructions on 
obtaining the licensed vaccinia vaccine, contact Drug Services, National Center for Infectious Diseases, CDC at (404) 639-3670.
Recombinant Vaccinia Vaccine Patient Care Implications, Contraindications and Potential 
Complications 
Patient Care Implications and ContraindicationsCover vaccination sites with  a sterile dry dressing ( e.g., Telfa pad). Instruct patients on proper hand-
hygiene, sterile dressing care, bathing, laundering of clothing, etc. Treat patient bandages or dressings 
removed from the vaccination site as infectious wa ste and dispose in appropriate biohazard containers. 
Do not administer the recombinant vaccinia vaccine if the recipient, or for at least three weeks after 
vaccination, their close househol d contacts (close household cont acts are those who share housing 
or have close ph ysical contact): 
xhave active eczema or a history of eczema or atopic dermatitis, or Darier’s disease.
xhave other acute, chronic, or exfoliative skin conditions ( e.g., burns, impetigo, varicella zoster, 
severe acne, contact dermatitis, psoriasis, herp es or other open rashes or wounds), until the 
condition resolves.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
62xare pregnant or intend to become  pregnant (due to the potential risk of fetal vaccinia); or are 
breast-feeding (due to the potential risk of c ontact transmission and in advertent inoculation). 
It is currently unknown if vaccinia virus or antibodies are excreted in breast milk. Patients 
(i.e., vaccinees) should avoid fathering a child for at least 4 months following completion of 
therapy with the recombinant vaccine.
xare in close contact with children less than 3 years of age (due to the potential risk of contact transmission and inadve rtent inoculation).
xare immunodeficient or immunocompromised (by di sease or therapy), including individuals 
with HIV infection.
Additionally, do not administer the recombinant vaccinia vaccine if the vaccinee:
xhas a moderate or severe acute illness, until the illness resolves.
xis undergoing topical steroid th erapy for inflammatory eye di seases, or undergoing therapy 
with systemic steroids; poten tial immune suppression increases risk for vaccinia-related 
complications.
xAt this time, until a more definitive causal relationship is determined, it is recommended that 
patients with known CHF or  clinically significant cardiomyopathy, not be vaccinated with 
recombinant vaccinia-based vaccines, due to the potential for development of myocarditis 
and/or pericarditis. 
Although the CDC believes that there is no eviden ce to conclude that the licensed vaccinia 
vaccine used in the Smallpox Vaccination Program causes angina or heart attacks, it acknowledges a possible causal relationship between the vaccina tion and heart inflammation.  
The CDC continues to study the relationship, but in the meantime, recommends excluding 
individuals with underlying heart disease from participation in the current Smallpox Vaccination Program. Patients are being immunized with recombinant vaccinia vaccines with therapeutic intent and will be evaluated for cardiovascular risk factors and recent or symptomatic cardiac events per protocol eligibility criteria. Patients will be encouraged to minimize cardiovascular disease risks and encouraged to follow risk reduction according to standard medical practice. 
Due to the method of manufacturing (virus gr own in primary chicken embryo dermal cells), 
do not administer the recombinant vaccinia vaccine  to patients with a history of allergy to 
eggs or egg products. Do not administer the r ecombinant vaccinia vaccine to patients with a 
history of allergy or serious react ion to prior vaccinia vaccination ( e.g., smallpox 
vaccination).
Potential Complications Associated With Recombinant Vaccinia VaccinationWhen vaccinia vaccine is administered by scarification for vaccination against smallpox, expected 
local reactions in individuals that have not previously been vaccinated with vaccinia include the appearance of a red papule in 3-4 days, followe d by vesiculation in 5-6 days, and then the 
formation of a pustule on days 8-9. A large area of erythema may surround the vesicle and pustule. A crusted scab usually forms by the second week and sloughs by the third week, leaving a well-
formed scar. Maximal viral shedding occurs from days 4-14, but can continue until the scab is shed 
from the skin. Other normal local reactions can include development of local satellite lesions, regional lymphadenopathy that can persist for weeks following healing of the skin lesion, 
considerable local edema, and intense inflammation from the vaccination ( i.e., viral cellulites), 
which may be confused with bacterial cellulites.  Systemic symptoms typically occur between 8-
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
6310 days post-vaccination and include fever, malaise, headache, chills, nausea, myalgia, local 
lymphadenopathy, soreness and intense eryt hema surrounding the vaccination site.
When administered by scarification in individuals  that have previously been vaccinated with 
vaccinia, expected local reactions include the appearance of a clear cut pustule 6-8 days following vaccination or the development of an area of de finite induration around a central lesion that may 
be an ulcer or scab 6-8 days following vaccination. The response to re-vaccination depends on the degree of residual immunity following previous  vaccination. Similar systemic symptoms may 
occur, but typically at a lower frequency. 
When recombinant vaccinia vaccines are administere d by intradermal, intralesional, subcutaneous 
or intramuscular routes of injection, milder lo cal reactions are expect ed, but similar systemic 
symptoms may occur.There have been a number of complications reported in the literature associated with vaccinia 
vaccination for smallpox. Reported complications from vaccinia vaccine when given by 
scarification include: a) auto-inoculation of other sites with vaccinia, b) generalized vaccinia, c) 
eczema vaccinatum, d) progressive vaccinia (vaccinia necrosum), or e) post-vaccinial encephalitis.  In a 1968 ten-state survey, cases of these complications per million vaccinations in adult recipients (> 20 years of age) of vaccinia primary vaccination and revaccination were:
Primary Vaccination Revaccination
auto-inoculation 606.1 25
generalized vaccinia 212.1 9.1
eczema vaccinatum 30.3 4.5
progressive vaccinia none reported 6.8
postvaccinial encephalitis none reported 4.5
Based on a 1968 national survey, the number of deat hs in primary vaccinees  was approximately 1 
per million and the number of deaths in recipien ts of revaccination was approximately 0.25 per 
million. Deaths were most often th e result of postvaccinial encepha litis or progressive vaccinia.
Information has been reported by the US Department of Defense (DoD) during the post-vaccination surveillance assessment of adve rse events in military personnel following 
implementation of a Smallpox Vaccination Program from the period of December 13, 2002 
through May 28, 2003. Although not directly comparable to historical numbers, due todifferences in multiple population variables, estimated cases (number of cases per million 
vaccinations based on vaccination of 450,293 pers onnel, with a median age of 26 years and 
70.5% as primary vaccinees) of these same complications per million vaccinations were:
auto-inoculation 107
generalized vaccinia 80
eczema vaccinatum none reported
progressive vaccinia none reported
postvaccinial encephalitis 2.2
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
64Generally, self-limited adverse reactions that can be serious, but not life-threatening include 
autoinoculation, erythematous and urticarial rashes, and ge neralized vaccini a. More serious 
life-threatening complications include progre ssive vaccinia, eczema vaccinatum, and post-
vaccinial encephalitis/encephalomyelitis. The complications of vaccinia vaccination may 
involve a number of different reactions:
1.Non-specific erythematous or urticarial rashes: These rashes can appear approximately 
10 days after vaccination and may sometimes be confused with generalized vaccinia, but are generally self-limiting. Patients are usually afebrile and these benign rashes usually resolve spontaneously within 2-4 days. Erythema multiforme can present as different types of lesions, including macules, papules, urti caria, and bull’s eye lesions (dark papule or 
vesicle surrounded by a pale zone and an area of erythema). These lesions may be 
extremely pruritic, lasting up to four weeks. Rarely, more serious bullous erythema multiforme (Stevens-Johnson syndrome) may oc cur, requiring hospitalization. Vaccinia 
Immune Globulin (VIG) therapy is not indicat ed to treat these rashes. Supportive care 
measures are warranted since these rashes ar e likely manifestations of an immune response 
or hypersensitivity reaction to the vaccine and are not likely to contain vaccinia virus.
2.Bacterial Infection: Vaccination site infection, most likely due to staphylococcus and 
streptococcus normal skin flora, is rare. Onset is approximately 5 days post-vaccination and is more common in children. Appropriate antibiotic therapy is required.
3.Inadvertent Inoculation : This can occur in the vaccinee (autoinoculation) as well as in 
close contacts (contact transmission). Accidental infection is the most common complication of vaccinia vaccination, ac counting for approximately 50% of all 
complications associated with  vaccination and revaccination. This usually results from 
autoinoculation of vaccinia virus transferred from the site of the vaccination. Sites typically involved include the face, eyelids, nose, mout h, genitalia, or rectum, but can also involve 
the arms, legs, and trunk. Contact transmission  of vaccinia, with accompanying toxicities, 
may occur when a recently vaccinated individual has contact with a susceptible individual.  
In a 1968 ten-state survey, contact transmissions were reported to occur at a rate of 27 infections per million vaccinations.  The age group in which contact transmission occurred 
most commonly was in children d 5 years. Eczema vaccinatum as a result of contact 
transmission may result in a more severe syndrome than that seen in vaccinees, perhaps 
because of multiple simultane ous inoculations. About 30% of eczema vaccinatum cases 
reported in the 1968 ten-state survey were a resu lt of contact transmission. It is possible 
that the number of cases of contact transmi ssion would be greater in today’s population, 
due to a largely unvaccinated patient population against sma llpox. Contact transmission 
rarely results in postvaccinial encephalitis or progressive vaccinia. Most cases of 
inadvertent inoculation usually resolve without  specific therapy and resolution of lesions 
follow the same course as the vaccination s ite in immunocompetent individuals. VIG can 
be used for severe cases involving extensive lesions or if comorbid conditions exist. VIG 
is contraindicated in the presence of isolated keratitis due to the risk of increased corneal scarring. VIG use can be considered in cases  of ocular implanta tion, with keratitis, if 
vision-threatening or if other life-threatening vaccinia-related complications exist that require VIG therapy.  
4.Generalized vaccinia: Generalized vaccinia (GV) is characterized by a disseminated 
maculopapular or vesicular rash of varying extent on any part of the body and typically 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
65develops 6-9 days after vaccination. The lesions  follow the same course as the vaccination 
site lesion. The lesions are he matogenously spread and may contain vaccinia virus. In 
immunocompetent individuals, the rash is generally self-limiting and requires supportive 
care therapy. VIG treatment can be used in severe cases for patients who are systemically 
ill and whose condition might be toxic or w ho have serious underl ying immunosuppressive 
illnesses.The differential diagnosis of GV includes  eczema vaccinatum, erythema multiforme, 
inadvertent inoculation at multiple sites, and uncommonly, early stages of progressive vaccinia or other vesicular diseases ( e.g., severe chickenpox or disseminated herpes). 
Several publications have inve stigated the reporting of GV among those individuals who 
received smallpox vaccinations during 2003.  Out of 38,440 vaccine recipients, 29 reports of possible GV during January 2003–Decembe r 2003 were identified but only 2 reports
met the case definition. More than 75% of the reports received a final diagnosis of 
hypersensitivity reaction or nonspecific rash af ter review by dermatologists or because 
laboratory results were negative for vaccini a and other orthopoxviruses.  Of 74 cases 
investigated in 753,226 smallpox vaccina tions administered in December 2002 to 
December 2004, 50 (67.6%) met the case definition of possible GV.  Cases occurred more frequently in primary vaccinees (rate, 81 per 1 million vaccinees) than in those 
revaccinated (rate, 32 per 1 million vaccinees).   However, none met the case definition of 
probable or confirmed GV, including 15 with vi rologically negative laboratory evaluations 
(e.g., culture, polymerase chain reaction, or skin biopsy).  Twenty-one reports of postscab 
lesions were made between January and August 2003 among 37,542 smallpox vaccinees.  
The lesions (scab and/or fluid) of seven patients were  tested for vaccinia virus by use of 
polymerase chain reaction and/or immunohistoche mistry; all were found to be negative.  
In addition, the postscab lesions of four of th e patients were biopsied.  The results from 
two of the biopsies suggested an allergic c ontact dermatitis, and results of one each 
demonstrated chronic dermatitis  and squamous cell carcinoma.  None of the four biopsied 
lesions had histologic evidence of viropathic  changes and no evidence supported smallpox 
vaccination as a cause for any of the lesions.  
5.Eczema vaccinatum: Eczema vaccinatum is a serious complication in persons with 
eczema and other types of chronic or exfoliative skin conditions. It can also occur among eczematous contacts of recently vaccinated persons. Vaccinial lesions (generalized papular, vesicular or pustular le sions) develop on areas of the skin that are, or had at one 
time been, eczematous. These areas become highly inflamed and lesions may spread to healthy skin. The rash is often accompanied by fever and individuals are systemically ill. The fatality rate for untreated cases (prior to availability of VIG) has been reported from 30-40%. Following availability of VIG, mortality was reduced to approximately 7%. Early diagnosis and prompt treatment with VI G is necessary to reduce mortality. 
6.Progressive vaccinia: Progressive vaccinia is the most serious cutaneous complication,
occurring when the local vaccination lesion fails to heal and develops progressive necrosis, 
with destruction of large areas of skin, su bcutaneous tissue, and underlying structures. 
Progressive lesions may spread to other skin su rfaces and to bone and viscera.   Progressive 
vaccinia is associated with a high mortality rate. This complication has been seen in patients with a compromised immune system due to a congenital deficiency, lymphoproliferative disease, immunosuppressive treatment, or HIV infection.Management should include aggressive VIG therapy.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
667.Post-Vaccinial Encephalitis/Encephalomyelitis : Vaccinial complications affecting the 
CNS are unpredictable. Post-vaccinial encephaliti s typically affects children < 2 years of 
age and is characterized by an onset of sy mptoms 6-10 days following vaccination, which 
include seizures, hemiplegia, aphasia, and transient amnesia. Histopathological changes 
include generalized cerebral edema, mild ly mphocytic meningeal infiltration, ganglion 
degenerative changes and perivascular hemorrh ages. Older children and adults can develop 
encephalitis or encephalomyelitis characterized by an onset of symptoms 11-15 days following vaccination, which include fever, vomiting, headache, mala ise, and anorexia, 
progressing to loss of consciousness, amnesi a, confusion, disorientation, restlessness, 
delirium, drowsiness, seizures and coma. Histopathological changes include demyelination 
with lymphocytic infiltration, but limited cerebral edema. Mortality rates have ranged from 15-25%, with 25% of patients who recover being left with va rying degrees and types of 
neurological deficits. VIG has not been shown to be effective in treating CNS disease and 
is not recommended. Post-vaccinial encepha litis/encephalomyelitis are diagnoses of 
exclusion and are not believed to be a result of  replicating vaccinia virus.  Although no 
specific therapy exists, supportive care, antic onvulsants, and intensive care might be 
required. A review of vaccinia-related deat hs (68) during a 9-year period (1959–1966 and 
1968) revealed that among first-time vaccines, 36 (52%) patients died as a result of post-
vaccinial encephalitis.  
8.Fetal Vaccinia : Fetal vaccinia is a rare, but serious complication following vaccinia 
vaccination during pregnancy or shortly before conception (e.g., within four weeks).  To date, fewer than 50 cases have been reported  and often result in fe tal or neonatal death. 
Efficacy of VIG therapy in a viable infant or used prophylactically in women during pregnancy is unknown. The CDC has estab lished a National Smallpox Vaccine in 
Pregnancy Registry. This registry will follow women during their pregnancies and their babies, after they are born, to determine the outcome of such pregnancies. The CDC can 
be contacted at (404) 639-8253.
9.Myocarditis/Pericarditis: The CDC has recommended a temporary medical deferral to 
the voluntary Smallpox Vaccination Program for persons with heart disease or cardiovascular risk factors (March 25, 2003) and issued “interim supplementary 
information” regarding evidence that smallp ox vaccination may cause myocarditis and/or 
pericarditis (March 31, 2003) in people recently vaccinated with the smallpox vaccine. The cardiac events reported include myocardial infarction, angina, myocarditis, pericarditis, 
and myopericarditis. Although the CDC believes that there is no evidence to conclude that the licensed vaccinia vaccine causes angina or heart attacks, it acknowledges a possible causal relationship between the vaccination a nd heart inflammation.  The CDC continues 
to study the relationship, but in the mean time, recommends that individuals with 
underlying heart disease be excluded from participation in th e current Smallpox 
Vaccination Program. While it is currently not possible to fully evaluate the risk of cardiac events or the risk of myocarditis, pericarditis, or myopericarditis associated with vaccinia vaccination, it is reasonable to inform patients participating in studies using recombinant 
vaccinia virus of these reports and provide relevant guidance for evaluating these events. Further investigation from the ongoing vacci ne program may provi de additional data 
regarding an association or lack of association with cardiovascular disease. Patients are being immunized with recombinant vaccinia vacc ines with therapeutic intent and will be 
evaluated for cardiovascular ri sk factors and recent or symptomatic cardiac events per 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
67protocol eligibility criteria. Patients will be encouraged to minimize cardiovascular disease 
risks and encouraged to follow risk reduction according to standard medical practice. At 
this time the evidence for an association with myocarditis, pericarditis, or myopericarditis seems plausible, but a rare event.  If not  otherwise excluded, patients with known CHF or 
clinically significant cardiomyopathy re quiring treatment should be excluded from 
protocol eligibility.      Out of a total of 540,824 military personnel vaccinated with a New York City Board of Health strain of vaccinia from Decembe r 2002 through December 2003, 67 developed 
symptomatic myopericarditis.  In the 61 ECGs that were reviewed, an identifiable abnormality was evident in 46 (75.4%).  The most common abnormalities included ST-
segment changes observed evident in 40 pa tients (65.6%); 5 patie nts (8.2%) had normal 
variant early repolarization, and T-wave abnormalities were noted in 11 patients (18.0%).  
In addition, cardiac enzymes were elevated in 60 of 61 (98.4%) patients evaluated with this 
assay.  On follow-up of 64 patients, a ll patients had objectiv e normalization of 
electrocardiography, echocardiography, graded exercise testing, laboratory testing, and 
functional status; 8 (13%) reported atypical, non-limiting persistent chest discomfort.  
Among 37,901 health care workers vaccinated with  the identical strain, 21 myo/pericarditis 
cases were identified; 18 (86%) were revacinees. Twelve met criteria for either myocarditis or myopericarditis, and 9 met criteria for pericarditis only (6 suspected and 3 probable).  The severity of myo/pericarditis was mild, w ith no fatalities, although 9 patients (43%) 
were hospitalized.
Treatment of Vaccinia Vaccination Complications
Vaccinia Immune Globulin (VIG): First-line treatment of some of the complications of vaccinia 
caused by dissemination of vaccinia virus (sever e cases of inadvertent inoculation involving 
extensive lesions or if comorbid conditions exist, severe cases of generalized vaccinia in patients
that are systemically ill and whose condition mig ht be toxic or who have serious underlying 
immunosuppressive illnesses, eczema vaccinatum, and progressive vaccinia) is with VIG.  VIG is contraindicated, however, for the tr eatment of isolated vaccinial ke ratitis.  VIG is a sterile solution 
of the immunoglobulin fraction of pooled plasma from individuals inoculated with vaccinia 
vaccine.  VIG is only available through the CDC’s Strategic National Pharmaceutical Stockpile by contacting the CDC’s Clinician Information Line at 1-877-554-4625 or the Director's Emergency 
Operations Center (DEOC) at 770-488-7100. Upon re ceipt of a call from a patient or upon direct 
observation of a patient or cont act who manifests signs and symptoms of any of the above 
conditions, the investigator should place a call to the CDC as soon as possible: 1) to initiate review 
of the clinical case, 2) to seek consultation on th e appropriateness of VIG th erapy, 3) to determine 
the appropriate VIG dose and dosing method for administration, if VIG therapy is required, and 4) to determine how to access and have the appropriate doses of VIG delivered.  Early institution of VIG therapy is advised following recognition of clinical symptoms compatible with some vaccinia complications (eczema vaccinatum, severe generalized vaccinia, progressive vaccinia, and some cases of inadvertent inoculation).  The effectiveness of VIG therapy appears to be time dependent. VIG has not proven to be of be nefit in the treatment of pos t-vaccinial encephalitis, and is 
contraindicated for treatment of isolated vaccinial keratitis due to  the increased risk of corneal 
scarring.  A new IV formulation of VIG that has a lower level of aggregated protein allowing it to 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
68be used by either the IM or IV route is available through the CDC.  This formulation will most 
likely be preferred for administration and the CDC will instruct investigators regarding appropriate dosing and method of administrati on based on the formulation and availability.  There is no 
guarantee that VIG will successfully treat complications.  At present, there are no other anti-viral therapies of proven benefit for the treatment of vaccinia-related complications.
11.3 C
IDOFOVIR (VISTIDE ®, G ILEAD SCIENCES )
Cidofovir is an FDA-approved antiviral drug for the treatment of CMV retinitis among patients 
with AIDS. Cell-based in vitro studies and animal model studies ha ve demonstrated this agent’s 
antiviral activity against certain orthopoxviruses.   Currently, its efficacy in the treatment of 
vaccinia-related complications in humans is unknown.  According to the CDC, VIG is recommended as first line of therapy.  Cidofovir may be considered as a secondary treatment, 
and will only be used when VIG therapy is not effective [Medical Management of Smallpox (Vaccinia) Vaccine Adverse R eactions: Vaccinia Immune Globulin  and Cidofovir. Last updated 
September 28, 2009.  Available at:  http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-
adv-reactions.asp]. 
11.4 E NZALUTAMIDE 
Please see FDA-approved packet insert for Enzalutamide for complete agent information.
11.4.1 Description and formulation
Enzalutamide (XTANDI ©) is an androgen receptor inhibitor. The chemical name is 4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5- dimethyl -4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluoro- N-methylbenzamide. Enzalutamide is a white crystalline non-hygroscopic solid. It is 
practically insoluble in water. XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients ar e caprylocaproyl polyoxylglycerides, butylated 
hydroxyanisole, butylated hydroxytoluene, gela tin, sorbitol sorbitan solution, glycerin, purified 
water, titanium dioxide, and black iron oxide.
11.4.2 Source
Medivation and Astellas Inc.  have reviewed the proposed clinical  trial design and have agreed to 
provide enzalutamide for the trial. 
11.4.3 Storage
Store enzalutamide capsules at 20°C to 25°C (68°F to 77°F) in a dry place and keep the 
container tightly closed. Excursions permitted from 15°C to 30°C (59°F to 86°F).
11.4.4 Stability
The company providing the IND drug will also provide the expiration date for each lot allocated 
to this study.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
6911.4.5 Dosage and Administration
Enzalutamide 160 mg (four 40 mg capsule s) administered orally once daily.
Swallow capsules whole. Enzalutamide can be taken with or without food.
11.4.6 Adverse EffectsSeizure
In the randomized clinical trial, 7 of 800 (0.9%) patients treated with enzalutamide 160 mg once daily experienced a seizure. No seizures occurr ed in patients treated with placebo. Seizures 
occurred from 31 to 603 days after initiation of enzalutamide. Patients experiencing seizure were permanently discontinued from therapy and all seizures resolved. There is no clinical trial experience re-administering enzalutamide to patie nts who experienced seizures. The safety of 
enzalutamide in patients with predisposing factors for seizure is not known because these patients were excluded from the trial. These exclusion criteria included a history of seizure, underlying brain injury with loss of consciousness,  transient ischemic attack within the past 12
months, cerebral vascular accident , brain metastases, brain arteriovenous malformation or the use 
of concomitant medications that may lower the seizure threshold. Because of the risk of seizure associated with enzalutamide use, patients should be advised of the risk of engaging in any
activity where sudden loss of consciousness could cause serious harm to themselves or others.
Other adverse events 
7KHPRVWFRPPRQDGYHUVHGUXJU HDFWLRQVUHSRUWHGLQSDWLH QWVUHFHLYLQJHQ]DOXWDPLGHLQ
the randomized clinical trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskele tal pain, headache, upper resp iratory infection, muscular 
weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and
cauda equina syndrome, hematuria,  paresthesia, anxiety, and hypertension. Grade 3 and higher 
adverse reactions were reported among 47% of  enzalutamide-treated patients and 53% of 
placebo-treated patients. Disconti nuations due to adverse events were reported for 16% of 
enzalutamide-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the 
enzalutamide-treated patients compared to none (0%) of the placebo-treated patients.
Laboratory Abnormalities
In the randomized clinical trial, Grade 1- 4 neutropenia occurred in 15% of patients on 
enzalutamide (1% Grade 3-4) and in 6% of patie nts on placebo (no Grade 3-4). The incidence of 
Grade 1-4 thrombocytopenia was similar in both arms; 0.5% of patients on  enzalutamide and 1% 
on placebo experienced Grade 3-4 thrombocytopenia. Grade 1-4 elevations in ALT occurred in 10% of patients on enzalutamide (0.3% Grade 3-4) and 18% of patients on placebo (0.5% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients on enzalutamide and 2% of patients on placebo.
Infections
In the randomized clinical trial, 1.0% of patients trea ted with enzalutamide compared to 0.3% of 
patients on placebo died from infections or sepsis. Infection-relate d serious adverse events were 
reported in approximately 6% of the patients on both treatment arms.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
70Falls and Fall-related Injuries
In the randomized clinical trial, falls or injuries related to falls occurred in 4.6% of patients treated with enzalutamide compared to 1.3% of patients on placebo. Falls were not associated with loss of consciousness or seizur e. Fall-related injuries were more severe in patients treated 
with enzalutamide and included non-pathologic  fractures, joint injuries, and hematomas.
HallucinationsIn the randomized clinical trial,  1.6% of patients treated with en zalutamide were reported to have 
Grade 1 or 2 hallucinations compared to 0.3%  of patients on placebo. Of the patients with 
hallucinations, the majority were on opioid-containing medications at the time of the event. Hallucinations were visu al, tactile, or undefined.
11.4.7 Drug Interactions
Drugs that Inhibit or Induce CYP2C8
Co-administration of a strong CYP2C8 inhib itor (gemfibrozil) increased the composite area 
under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl 
enzalutamide in healthy volunteers. Co-administr ation of enzalutamide with strong CYP2C8 
inhibitors should be avoided if possible. If co-administration of enzalutamide with a strongCYP2C8 inhibitor cannot be avoide d, reduce the dose of enzalutamide .
The effects of CYP2C8 inducers on the pharm acokinetics of enzalutamide have not been 
evaluated in vivo .
Co-administration of enzalutamide with strong or moderate CYP2C8 inducers (e.g., rifampin) may alter the plasma exposure of enzalutamide and should be avoided if possible. Selection of a 
concomitant medicati on with no or minimal CYP2C8 induction potential is recommended.
Drugs that Inhibit or Induce CYP3A4Co-administration of a strong CYP3A4 inhibito r (itraconazole) increased the composite AUC of 
enzalutamide plus Ndesmethyl enzaluta mide by 1.3 fold in healthy volunteers 
The effects of CYP3A4 inducers on the pharm acokinetics of enzalutamide have not been 
evaluated in vivo .
Co-administration of enzalutamide with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decr ease the plasma exposure of 
enzalutamide and should be avoided if possible.  Selection of a concomita nt medication with no 
or minimal CYP3A4 induction potential is r ecommended. Moderate CYP3A4 inducers (e.g., 
bosentan, efavirenz, etravirine, modafinil, nafcillin) and St. John’s Wort may also reduce the plasma exposure of enzalutamide a nd should be avoided if possible.
Effect of Enzalutamide on Drug Metabolizing Enzymes
Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in 
humans. At steady state, enzalutamide reduced  the plasma exposure to midazolam (CYP3A4 
substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of enzalutamide with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
71and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., proton pump inhibitors 
(lansoprazole, omeprazole, pant oprazole, rabeprazole) and clopidogrel.) should be avoided, as 
enzalutamide may decrease their exposure. If co -administration with wa rfarin cannot be avoided, 
conduct additional INR monitoring.
12 REFERENCES
1. Furr BJ. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: 
preclinical studies. Horm Res. 1989;32 S uppl 1:69-76. Epub 1989/01/01. PubMed PMID: 
2533159.
2.Chen Y, Clegg NJ, Scher HI. Anti-androgens a nd androgen-depleting therapies in prostate 
cancer: new agents for an established ta rget. The lancet oncology. 2009;10(10):981-91. Epub 
2009/10/03. doi: 10.1016/S1470-2045(09)70229-3. PubMed PMID: 19796750; PubMed Central PMCID: PMC2935850.
3.Sartor AO, Tangen CM, Hussain MH, Eisenbe rger MA, Parab M, Fontana JA, et al. 
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group 
trial (SWOG 9426). Cancer. 2008;112(11):2393-400. Epub 2008/04/03. doi: 10.1002/cncr.23473. PubMed PMID: 18383517.
4.Small EJ, Halabi S, Dawson NA, Stadler WM , Rini BI, Picus J, et al. Antiandrogen 
withdrawal alone or in combination with ke toconazole in androgen -independent prostate 
cancer patients: a phase III trial (CALGB  9583). J Clin Oncol. 2004;22(6):1025-33. Epub 
2004/03/17. doi: 10.1200/JCO.2004.06.037JCO.2004.06.037 [pii]. PubMed PMID: 15020604.
5.FDA. Enzalutamide (XTANDI Capsules)  [September 4, 2012]. Available from: 
http://www.fda.gov/Drugs/InformationOnD rugs/ApprovedDrugs/ucm317997.htm?source=gov
delivery.
6.Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity 
of MDV3100 in castration-resistant prosta te cancer: a phase 1-2 study. Lancet. 
2010;375(9724):1437-46. Epub 2010/04/20. doi: S0140-6736(10)60172-9 [pii]
10.1016/S0140-6736(10)60172-9. PubMed PMID: 20398925; PubMed Central PMCID: PMC2948179.
7.Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, et al. Increased Survival 
with Enzalutamide in Prosta te Cancer after Chemotherapy. N Engl J Med. 2012. Epub 
2012/08/17. doi: 10.1056/NEJMoa1207506. PubMed PMID: 22894553.
8.Sharifi N, Gulley JL, Dahut WL. Androgen de privation therapy for prostate cancer. JAMA : 
the journal of the American Medical A ssociation. 2005;294(2):238-44. Epub 2005/07/15. doi: 
10.1001/jama.294.2.238. PubMed PMID: 16014598.
9.Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the 
immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957-71. Epub 2007/06/16. doi: 2441 [pii]. PubMed PMID: 17569623.
10.Tay MH, Kaufman DS, Regan MM, Leibowitz SB , George DJ, Febbo PG, et al. Finasteride 
and bicalutamide as primary hormonal therapy in patients with advan ced adenocarcinoma of 
the prostate. Annals of oncology : official journal of the European Society for Medical 
Oncology / ESMO. 2004;15(6):974-8. Epub 2004/05/21. PubMed PMID: 15151957.
11.Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al. 
Bicalutamide monotherapy versus fl utamide plus goserelin in pros tate cancer pa tients: results 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
72of an Italian Prostate Cancer Project study. J ournal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 1999;17(7):2027-38. Epub 1999/11/24. PubMed 
PMID: 10561254.
12.Rini BI. Technology evaluation: APC-8015, De ndreon. Curr Opin Mol Ther. 2002;4(1):76-9.
PubMed PMID: 11883698.
13.Patel PH, Kockler DR. Sipuleu cel-T: a vaccine for metasta tic, asymptomatic, androgen-
independent prostate cancer. Ann Pharm acother. 2008;42(1):91-8. PubMed PMID: 18094343.
14.Kantoff PW, Higano CS, Shore ND, Berger ER , Small EJ, Penson DF, et al. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
Epub 2010/09/08. doi: 10.1056/NEJMoa1001294. PubMed PMID: 20818862.
15.Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based 
vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18(7):1001-11.
Epub 2009/06/25. doi: 10.1517/13543780902997928. PubMed PMID: 19548854.
16.Madan RA, Bilusic M, Heery C, Schlom J, Gu lley JL. Clinical evaluation of TRICOM vector 
therapeutic cancer vaccines. Semin Oncol. 2012;39(3):296-304. Epub 2012/05/19. doi: 
S0093-7754(12)00051-6 [pii]
10.1053/j.seminoncol.2012.02.010. PubMed PMID: 22595052; PubMed Central PMCID: PMC3398615.
17.Arlen PM, Mohebtash M, Madan RA, Gulle y JL. Promising novel immunotherapies and 
combinations for prostate cancer. Futu re Oncol. 2009;5(2):187-96. Epub 2009/03/17. doi: 
10.2217/14796694.5.2.187. PubMed PMID: 19284377; PubMed Central PMCID: PMC2705770.
18.Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol 
Ther. 2004;4(4):575-88. PubMed PMID: 15102606.
19.Longo DL. New therapies for castration-resist ant prostate cancer. The New England journal 
of medicine.363(5):479-81. PubMed PMID: 20818868.
20.Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall 
survival analysis of a phase II randomized c ontrolled trial of a Poxviral-based PSA-targeted 
immunotherapy in meta static castration-resistant pr ostate cancer. J Clin Oncol. 
2010;28(7):1099-105. PubMed PMID: 20100959.
21.Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and 
prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Ca ncer Immunol Immunother. 
2010;59(5):663-74. Epub 2009/11/06. doi: 10.1007/s00262-009-0782-8. PubMed PMID: 
19890632; PubMed Central PMCID: PMC2832083.
22.clinicaltrials.gov. A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to 
Treat Metastatic Pr ostate Cancer (Prospect) [cited 2012 August 1]. Available from: 
http://clinicaltrials.gov/ct2/show /[STUDY_ID_REMOVED]?term=PROSPECT&rank=6.
23.Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell 
infiltration of the prostate induced by androgen  withdrawal in patients with prostate cancer. 
Proceedings of the National Academy of Sciences of the United States of America. 2001;98(25):14565-70. PubMed PMID: 11734652.
24.Goldberg GL, Sutherland JS, Hammet MV, Milton MK, Heng TS, Chidgey AP, et al. Sex 
steroid ablation enhances lymphoid recovery fo llowing autologous he matopoietic stem cell 
transplantation. Transplantation. 2005;80(11):1604-13. PubMed PMID: 16371932.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
7325.Drake CG, Doody AD, Mihalyo MA, Huang CT, Ke lleher E, Ravi S, et al. Androgen ablation 
mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer cell. 
2005;7(3):239-49. PubMed PMID: 15766662.
26.Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. 
Activation of thymic regeneration in mice a nd humans following androgen blockade. J 
Immunol. 2005;175(4):2741-53. PubMed PMID: 16081852.
27.Vaccine Therapy With PROSTVAC/TRICOM an d Flutamide Versus Flutamide Alone to 
Treat Prostate Cancer  [cited 2012 August 5]. Available from: http://clinicaltrials .gov/ct2/show/[STUDY_ID_REMOVED].
28.Bubley GJ, Carducci M, Dahut W, Dawson N, Da liani D, Eisenberger M,  et al. Eligibility and 
response guidelines for phase II clinical tria ls in androgen-independe nt prostate cancer: 
recommendations from the Prostate-Specifi c Antigen Working Group. J Clin Oncol. 
1999;17(11):3461-7. Epub 1999/11/05. PubMed PMID: 10550143.
29.Bilusic M, Gulley JL, Heery C, Apolo AB, Arlen P, Rauckhorst M, et al. A randomized phase 
II study of flutamide with or without PSA -TRICOM in nonmetastatic castration-resistant 
prostate cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 163).
30.Scher HI, Halabi S, Tannock I, Morris M, St ernberg CN, Carducci MA, et al. Design and end 
points of clinical trials for pa tients with progressive  prostate cancer and castrate levels of 
testosterone: recommenda tions of the Prostate Cancer Clinical Trials Working Group. J Clin 
Oncol. 2008;26(7):1148-59. Epub 2008/03/04. doi: 26/7/1148 [pii]10.1200/JCO.2007.12.4487. PubMed PMID: 18309951.
31.Hurwitz AA, Foster BA, Allison JP, Gree nberg NM, Kwon ED. The TRAMP mouse as a 
model for prostate cancer. Curr Prot oc Immunol. 2001;Chapter 20:Unit 20 5. Epub 
2008/04/25. doi: 10.1002/0471142735.im2005s45. PubMed PMID: 18432778.
32.Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host 
immune response elements and vaccine combin ation therapy. Int J Cancer. 2012;130(8):1948-
59. Epub 2011/06/03. doi: 10.1002/ijc.26219. PubMed PMID: 21633954; PubMed Central PMCID: PMC3232304.
33.Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine 
enhances T-cell responses and antitumor ac tivity: effects of docetaxel on immune 
enhancement. Clin Cancer Res. 2008;14( 11):3536-44. Epub 2008/06/04. doi: 14/11/3536 [pii]
10.1158/1078-0432.CCR-07-4025. PubMed PMID: 18519787; PubMed Central PMCID: PMC2682419.
34.Aymeric L, Apetoh L, Ghiringhelli F, Tesniere  A, Martins I, Kroemer G, et al. Tumor cell 
death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010;70(3):855-8. Epub 2010/01/21. doi: 0008-5472.CAN-09-3566 [pii]10.1158/0008-5472.CAN-09-3566 [doi]. PubMed PMID: 20086177.
35.Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the 
ensuing immune response. Cell Death Differ. 2008;15(1):21-8. Epub 2007/11/10. doi: 4402266 [pii]10.1038/sj.cdd.4402266. PubMed PMID: 17992190.
36.Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent a ndrogen suppression in 
the management of prostate cancer. Urol ogy. 1999;53(3):530-4. Epub 1999/03/30. PubMed 
PMID: 10096379.
37.Klotz L, O'Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, et al. A phase III 
randomized trial comparing inte rmittent versus continuous androgen suppression for patients 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
74with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK 
Intercontinental Trial CRUKE/01/013. J Clin Oncol 29: 2011 (suppl 7; abstr 3) 
38.Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, et al. Analysis of 
circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunothe r. 2011;60(2):197-206. Epub 2010/10/27. doi: 
10.1007/s00262-010-0927-9. PubMed PMID: 20976449; PubMed Central PMCID: PMC3202216.
39.Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular 
characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3-12. Epub 
2007/11/17. doi: 4402269 [pii]10.1038/sj.cdd.4402269 [doi]. PubMed PMID: 18007663.
40.Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved 
survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. Epub 2010/06/08. doi: NEJMoa1003466 [pii]10.1056/NEJMoa1003466. PubMed PMID: 20525992.
41.Madan RA, Gulley JL, Fojo T, Dahut WL. Therap eutic cancer vaccines in prostate cancer: the 
paradox of improved survival without changes in time to progression. Oncologist. 2010;15(9):969-75. Epub 2010/08/28. do i: theoncologist.2010-0129 [pii]
10.1634/theoncologist.2010-0129. PubMed PM ID: 20798195; PubMed Central PMCID: 
PMC3228037.
42.Stein WD, Yang J, Bates SE, Fojo T. Bevacizu mab reduces the growth ra te constants of renal 
carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. The oncologist. 2008;13(10):1055-62. Epub 2008/10/02. doi: 10.1634/theoncologist.2008-0016. PubMed PMID: 18827177.
43.Stein WD, Wilkerson J, Kim ST, Huang X, Fojo AT, Motzer RJ, et al. Analyzing the pivotal 
trial that compared sunitinib and interferon alfa in renal ce ll carcinoma, using a method that 
assesses tumor regression and growth. Clin Cancer Res. 2012. Epub 2012/02/22. doi: 1078-
0432.CCR-11-2275 [pii]10.1158/1078-0432.CCR-11-2275. PubMed PMID: 22344231.
44.Stein WD, Gulley JL, Schlom J, Madan RA, Dahu t W, Figg WD, et al. Tumor regression and 
growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clinical cancer research: an official journal of the American Association for Cancer Re search. 2011;17(4):907-17. Epub 2010/11/26. doi: 
10.1158/1078-0432.CCR-10-1762. PubMed PMID: 21106727.
45.DiPaola RS, Chen Y, Bubley GJ, Hahn NM, Stei n M, Schlom J, et al., editors. A phase II 
study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA pr ogression after local therapy for prostate cancer: Results of 
ECOG 9802. Genitourinary Cancers Symposium 2009.
46.Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of 
autologous cellular immunotherapy with sipuleuce l-T in androgen-dependent prostate cancer. 
Clin Cancer Res. 2011;17(13):4558-67. Epub 2011/05/12. doi: 1078-0432.CCR-10-3223 [pii]10.1158/1078-0432.CCR-10-3223. PubMed PMID: 21558406.
47.Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY. A novel ELISPOT assay to 
enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1. J Immunol Methods. 2003;279(1-2):183-92. Epub 2003/09/13. 
doi: S0022175903001856 [pii]. PubMed PMID: 12969559.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
7548.Arlen P, Tsang KY, Marshall JL, Chen A, Stei nberg SM, Poole D, Horan Hand P, Schlom J, 
and Hamilton JM. The use of a rapid ELISPOT assay to analyze peptide-specific immune 
responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer 
Immunol. Immunother . 49: 517-529, 2000.
49.Crook JM, O’Callaghan CJ, Duncan G, et al. Intermitten androgen suppression for rising PSA 
level after radiotherapy. N Engl J Med. 367: 895-903, 2012.
50.Tombal, B., et al., Enzalutamide monotherapy in hormone-naive prostate cancer: primary 
analysis of an open-label, single-arm, pha se 2 study. Lancet Oncol, 2014. 15(6): p. 592-600.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
7613 APPENDIX A: PERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Descriptions
0Normal activity. Fully active, able 
to carry on all pre-disease performance without restriction.100Normal, no complaints, no evidence of disease.
90Able to carry on normal activity; minor signs or symptoms of disease.
1Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out light or sedentary work (e.g., light housework, office work).80Normal activity with effort; some signs or symptoms of disease.
70Cares for self, unable to carry on normal activity or to do active work.
2In bed < 50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about > 50% of waking hours.60Requires occasional assistance, but is able to care for most of his/her needs.
50Requires considerable assistance and frequent medical care.
3In bed > 50% of the time. Capable of only limited self-care, confined to bed or chair > 50% of waking hours.40Disabled, requires special care and assistance.
30Severely disable d, hospitalization 
indicated. Death not imminent.
4100% bedridden. Completely disabled. Cannot carry on any self-care.  Totally confined to bed or chair.20Very sick, hospitalization indicated. Death not imminent.
10Moribund, fatal processes progressing rapidly.
5 Dead. 0 Dead.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
7714 APPENDIX B: VACCINIA-PSA(L155)/TRICOM PATIENT INSTRUCTION SHEET
1. What vaccination site reactions can you expect?
2. How should you care for the vaccination site? 3. Are there any activities I should avoid?4. What about contact with other people?
5. Who do I contact when I have a question?
1. What vaccination site reactions can you expect?
A typical reaction in a patient who has been pr eviously vaccinated with vaccinia includes the 
appearance of a small swelling in 2-3 days that may enlarge to 1-2 inches across, a small blister or 
pustule after 5-7 days, and healing with little scarring within 2-3 weeks. Some patients may have very little skin reaction.   Often the leg that rece ived the vaccine may become swollen. Swollen or 
tender lymph nodes (“glands”) in the groin may be felt. A fever to 100-101 qF may occur on the 
second or third day.  You may notice that you feel  tired for 3 or 4 days. The vaccination site may 
itch for about 2 weeks while the scab is forming.  You can take acetaminophen ("Tylenol") if you 
have any aches or fever but should avoid aspirin.  If fever continues for more than a day or two, 
you should call to speak to the clin ic nurse or the research nurse. 
In patients who have never received vaccinia or in  some who received it a very long time ago, a 
red swelling is followed by a blisters on day 5 to 6 and then formation of a pustule (or "boil") 1-2inches in diameter on day 9 to 11.  A large area of redness may surround this area.  A crusted scab 
usually forms by the second week and falls off by the third week leaving a scar roughly 1/2 inch in diameter.  Fever and malaise (the "blahs") ma y occur during the blister and pustular phases. 
Swollen and tender lymph nodes may persist for months. Many of the local toxicities described 
(e.g., pustule and scab formation) are typical of reactions seen when vaccinia is administered via 
scarification or intradermal administration. These reactions may be seen, but are usually not seen when administered via subcutaneous injection.
2. How should you care for the vaccination site?
Live vaccinia virus is in skin cells at the vacc ination site during the 1-2 weeks until healing has 
occurred.  Maximal viral "shedding" from the va ccination site occurs from days 4-14, but can 
continue until the scab falls off from the skin. After that there is no vaccinia virus in your body.  You can spread the virus to other parts of your bod y or to other people by touching the vaccination 
site and then touching your eyes, mouth, a cut or some other break in the skin. You do not pass vaccinia virus by coughing or sneezing or  by sharing food or cups and dishes.
In general, frequent careful hand washing by you and by any persons in physical contact with you is the best way to prevent transmission of virus.   You should also use two types of barriers over 
your vaccination site at all times until the scab is  gone.  These barriers are (1) the bandage and (2) 
clothing (pants or elbow length sleeves dependi ng on the site of vaccination).  These barriers 
should remain in place until the scab has fallen off.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
78For dressing care you will have a bag with some no-stick "First-Aid" or "T elfa" pads, disposable 
gloves, and zip-lock plastic bags.  If you run out of supplies between visits, you can use a dry 
sterile bandage (gauze or "First-Aid" or "Telfa") from the drug store.
The no-stick pad ("First-Aid" or "Telfa" pad) dressi ng should be worn until the site has healed.  If 
it remains clean and dry and is not coming off, you do not need to change it.  If the dressing gets 
wet either from drainage from the vaccination or from water when y ou are showering or if it starts 
coming off, you should remove it and put on a clea n bandage.  Wear the gloves when handling the 
old dressings.  Put the old dressi ng and the gloves in the zip-lock bag, then wash your hands, put 
on the new bandage, and wash your hands again.  You do not need to wear gloves for the new 
bandage.  You do not need to wash the vaccinati on site, but while the dressing is off, you may 
wash it lightly with a cloth, soap, and water.  If you do wash, blot the site dry with a towel (don't 
rub), then put the wash cloth and the towel in the laundry.  Do not let the shower run on the 
unbandaged site because live virus could be washed  onto other areas on your body. Do not put any 
steroid cream, medicated creams, or other ointments on the vaccination site.
Before you throw away the zip-lock bag with th e old dressing and gloves in it, pour a little bleach 
(about a quarter cup) in the bag to help kill any virus.
Wash your hands after each step.
3. Are there any activities I sh ould avoid or take special care?
You should not go swimming until the vaccination site has healed and you no longer need to wear 
a bandage on it. 
If you wear contact lenses, have removable dentures, have a colostomy or any other "open" area on 
your body that needs daily care, always wash y our hands very well before  handling your contact 
lenses, dentures, dressings, etc.  Take care of all of these procedures before changing your 
vaccination dressing.
4. What about contact with other people?
Remember, frequent careful ha nd washing by you and by any persons with whom you have 
physical contact is the best way to prevent transmi ssion of virus.  During the time you need to wear 
a bandage (for 7-14 days after vaccination) there are several kinds of people with whom you 
should avoid close contact.  "Close contact" means that you sleep in the same bed with the person, give the person baths, and/or touch their bare sk in to change their clothes (or diapers), apply 
ointments, or change their bandages. 
The individuals you should avoid include children < 3years of age; pregnant women or nursing 
women; individuals with eczema, history of eczema  or other skin conditions such as active cases 
of extensive psoriasis, severe ra shes, generalized itching, infections, burns, chicken pox, or skin 
trauma; and/or immune s uppressed individuals such as indivi duals with leukemia or lymphoma, 
with AIDS, or those receiving immunosuppressive trea tment (for example, after organ transplant).  
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
795. Who do I contact when I have a question?
If you have any questions at any time, please call.   A nurse or a physician is available 24 hours a 
day by telephone.  To speak with your main doctor or with a clinic nurse, call the 
Hematology/Oncology Clinic betw een 8 AM and 4:30 PM Monday to Friday.  To speak with the 
research nurses, call the research nurse office  during the day; during nights, weekends, and 
sometimes during the day, when the research office is empty, you may leave a message for the research nurse on the answering machine.  You can call Dr. Ravi Madan or Dr. James Gulley any 
time during weekday hours.  In an emergency on weekends, evenings, or holidays, you can always get in touch with the MEDICAL ONCOLOGY DOCTOR ON CALL (listed below) The on call doctor will call you back.   If you have to go to an emergency room near your home, go to the hospital first, and then have the doctors there call for more information.
PHONE NUMBERS3 South East (301) 451-1152
12
thfloor Oncology Clinic (301) 496-4026*
Ravi Madan, MD (301) 480-7168*
James Gulley, MD, PhD (301) 480-7164*
*after clinic hours the NCI Medical Oncology physician On call through NIH pageoperator (301) 496-1211
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
8015 APPENDIX C : ON STUDY AND FOLLOW-UP EVALUATIONS
COHORT 1
Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
Prior to Enrollment Screening for eligibility, 
Informed consent, NIH 
Advanced Directives Form1Screening for eligibility, Informed consent, NIH Advanced Directives form
1
Within 8 weeks of initiating treatment*Apheresis , Lab work (HIV, 
Hep B and C), baseline scans (MRI/CT and bone scans),EKG*Apheresis , Lab work (HIV, Hep B 
and C), baseline scans (MRI/CT and bone scans), EKG
Within 16 days of beginning treatment (day -16 to day 1)Baseline history and physical exam, ECOG status, Research Blood, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein, TBNK, PSA, testosterone,PAP (prostatic acid phosphatase),dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
RandomizationBaseline history and physical exam, 
ECOG status, Research Blood, CBC, Acute, Hepatic, Mineral Panels, 
LDH, CK, Uric Acid, Total Protein, TBNK, PSA, testosterone, PAP (prostatic acid phosphatase),dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Randomization
Day 1 Enzalutamide day 1 month 1
(daily dose of 160 mg)Enzalutamide day 1 month 1 + 
PSA-TRICOM (Prostvac-V) dose 1
Week 3 Physical examination
Research Blood, CBC, Acute, Hepatic, Mineral Panels, LDH, 
CK, Uric Acid, Total Protein,Physical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Pa nels, LDH, CK, 
Uric Acid, Total Protein,
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
81Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
TBNK, PSA, testosterone,
PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
PSA-TRICOM (Prostvac-F) dose 1
Week 5 Physical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Panels, LDH, 
CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Enzalutamide day 1 month 2
(daily dose of 160 mg)Physical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Pa nels, LDH, CK, 
Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Enzalutamide day 1 month 2 + 
PSA-TRICOM (Prostvac-F) dose 2
Week 9 Physical examination
, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP, dihydrotestosterone (DHT), sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedionePhysical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
82Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
prolactin, estradiol
Enzalutamide day 1 month 3
(daily dose of 160 mg)Enzalutamide day 1 month 3 + 
PSA-TRICOM (Prostvac-F) dose 3
Week 13 Physical examination
, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
*Apheresis
Enzalutamide therapy is 
discontinuedPhysical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
*Apheresis
Enzalutamide therapy is 
discontinued
PSA-TRICOM (Prostvac-F) dose 4
Week 15 , CBC, Acute, Hepatic, 
Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
83Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
Week 17 Physical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Panels, LDH, 
CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiolPhysical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Pa nels, LDH, CK, 
Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
PSA-TRICOM (Prostvac-F) dose 5
Week 21 Physical examination
, CBC, Acute, Hepatic, 
Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiolPhysical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAPdihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
PSA-TRICOM (Prostvac-F) dose 6
Week 25 Physical examination
, CBC, Acute, Hepatic, 
Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone Physical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), 
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
84Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
(DHEA), luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
*Apheresisfollicle-stimulating hormone (FSH), 
androstenedioneprolactin, estradiol 
*Apheresis
PSA-TRICOM (Prostvac-F) is 
discontinued
Week 29 Physical examination
, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone,PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiolPhysical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Up to Week 52
Every 4 weeks **Physical examination, CBC, Acute, Hepatic, 
Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Research Blood (week 52 
only)Physical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total
Protein,
TBNK, PSA, testosterone, PAP,
dihydrotestosterone (DHT),
sex hormone-binding globulin 
(SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedione
prolactin, estradiol 
Research Blood (week 52 only)
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
85Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
Beyond Week 52
Every 8 weeks (+/-
7 days)**Physical examination
, CBC, Acute, Hepatic, 
Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol 
Research Blood (every 16 
weeks)Physical examination
, CBC, Acute, Hepatic, Mineral 
Panels, LDH, CK, Uric Acid, Total 
Protein,
TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),
sex hormone-binding globulin 
(SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedione
prolactin, estradiol 
Research Blood (every 16 weeks)
Once PSA reaches 
baseline valueRestaging Scans (MRI/CT and bone scans)Restaging scans (MRI/CT and bone scans)
Course 2, Week 1 Enzalutamide day 1 month 1,
course 2(daily dose of 160 mg)
Research labs including 
plasma VEGF levelsEnzalutamide day 1 month 1, course 2
Research labs including plasma 
VEGF levels
Course 2,Week 5 Physical examination
Research Blood, CBC, Acute, Hepatic, Mineral Panels, LDH, 
CK, Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating Physical examinationResearch Blood, CBC, Acute, Hepatic, Mineral Pa nels, LDH, CK, 
Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH),follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
86Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
hormone 
(FSH)androstenedioneprolactin, estradiol
Enzalutamide day 1 month 2
course 2(daily dose of 160 mg)Enzalutamide day 1 month 2 course 2
Course 2, Week 9 Physical examination
, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Enzalutamide day 1 month 3
course 2(daily dose of 160 mg)Physical examination, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total 
Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Enzalutamide day 1 month 3 course 2
Course 2, Week 13 Physical examination
Research Blood, CBC, Acute, 
Hepatic, Mineral Panels, LDH, 
CK, Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiolPhysical examinationResearch Blood, CBC, Acute, Hepatic, Mineral Pa nels, LDH, CK, 
Uric Acid, Total Protein,TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Research labs including plasma 
VEGF levels
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
87Arm A (Enzalutamide 
only)Arm B (Enzalutamide + PSA-
TRICOM)
Research labs including 
plasma VEGF levels
*Apheresis
Enzalutamide therapy is discontinued for course 2*ApheresisEnzalutamide therapy is discontinuedfor course 2
Every 4 weeks thereafterPhysical examination, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total Protein, TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Research Blood (every 16 
weeks)Physical examination, CBC, Acute, Hepatic, Mineral Panels, LDH, CK, Uric Acid, Total 
Protein, TBNK, PSA, testosterone, PAP,dihydrotestosterone (DHT),sex hormone-binding globulin (SHBG), dehydroepiandrosterone (DHEA), luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstenedioneprolactin, estradiol
Research Blood (every 16 weeks)
*Apheresis is not mandatory and will be scheduled based on availability 
-Patients may come off study before  week 52 as clinically indicated.
-All patient visits can be delayed by 1 week for logistical issues.
** Patients will be followed until PSA reaches baseline.  Patients who continue to be followed for rising PSA but have not requi red ADT may be seen beyond the study period.
The study period ends 52 weeks after enrollme nt unless patients rece ive a second course 
of enzalutamide, then study period ends 9 m onths after the end of the second course.
1As indicated in section 7.3, all subjects will be offered th e opportunity to complete an 
NIH advanced directives form.  This should be done preferably at baseline but can be done at any time during the study as long as the capacity to do so is retained.  The completion of the form is strong ly recommended, but is not required.
Version Date: 12/5/17
Abbreviated Title : Enzalutamide in non-met CSPC
8816 APPENDIX D: INSTRUCTIONS FOR PRE-STUDY AND FOLLOW-UP BLOOD 
TESTS
Blood Studies Blood Tube/Comments Destination
CBC with differential 1 light lavender tube CC De partment of 
Laboratory Medicine (DLM)
Hepatic Panel, Mineral Panel, 
Acute Care Panel, LDH, CK, 
Uric Acid, Total Protein1 4 mL SST CC DLM
Anti-HIV-1/2 1 8 mL SST CC TTV lab
Testosterone, total 1 red top tube CC DLM
Prostate Specific Antigen 4 mL SST CC DLM
Lymphocyte Phenotyping, TBNK1 light lavender tube CC DLM
Immunology Assays 6 10 mL Na Heparin tubes
2 7 ml SST tubesApheresis ProductNCI-Frederick1-301-846-5893
Serum VEGF 6mL EDTA tube Dr. Figg's lab - Blood 
Processing Core (BPC)